- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00262600
Evaluación aleatoria de la terapia anticoagulante a largo plazo (RE-LY) con etexilato de dabigatrán
Evaluación aleatoria de la terapia anticoagulante a largo plazo (RE-LY) que compara la eficacia y la seguridad de dos dosis ciegas de etexilato de dabigatrán con warfarina de etiqueta abierta para la prevención del accidente cerebrovascular y la embolia sistémica en pacientes con fibrilación auricular no valvular: prospectivo, multicéntrico , Ensayo de no inferioridad de grupos paralelos (estudio RE-LY)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania
- 1160.26.0932 Boehringer Ingelheim Investigational Site
-
Berlin, Alemania
- 1160.26.0948 Boehringer Ingelheim Investigational Site
-
Berlin, Alemania
- 1160.26.0962 Boehringer Ingelheim Investigational Site
-
Bochum, Alemania
- 1160.26.0940 Boehringer Ingelheim Investigational Site
-
Coburg, Alemania
- 1160.26.0936 Boehringer Ingelheim Investigational Site
-
Dachau, Alemania
- 1160.26.0968 Boehringer Ingelheim Investigational Site
-
Dortmund, Alemania
- 1160.26.0972 Boehringer Ingelheim Investigational Site
-
Duisburg, Alemania
- 1160.26.0957 Boehringer Ingelheim Investigational Site
-
Erlangen, Alemania
- 1160.26.0971 Boehringer Ingelheim Investigational Site
-
Eschweiler, Alemania
- 1160.26.0965 Boehringer Ingelheim Investigational Site
-
Essen, Alemania
- 1160.26.0934 Boehringer Ingelheim Investigational Site
-
Frankfurt/Main, Alemania
- 1160.26.0931 Boehringer Ingelheim Investigational Site
-
Heidelberg, Alemania
- 1160.26.0943 Boehringer Ingelheim Investigational Site
-
Kassel, Alemania
- 1160.26.0955 Boehringer Ingelheim Investigational Site
-
Köln, Alemania
- 1160.26.0963 Boehringer Ingelheim Investigational Site
-
Lahr, Alemania
- 1160.26.0946 Boehringer Ingelheim Investigational Site
-
Limburg, Alemania
- 1160.26.0944 Boehringer Ingelheim Investigational Site
-
Mainz, Alemania
- 1160.26.0951 Boehringer Ingelheim Investigational Site
-
Mannheim, Alemania
- 1160.26.0933 Boehringer Ingelheim Investigational Site
-
Mannheim, Alemania
- 1160.26.0945 Boehringer Ingelheim Investigational Site
-
Mannheim, Alemania
- 1160.26.0970 Boehringer Ingelheim Investigational Site
-
München, Alemania
- 1160.26.0947 Boehringer Ingelheim Investigational Site
-
München, Alemania
- 1160.26.0952 Boehringer Ingelheim Investigational Site
-
Papenburg, Alemania
- 1160.26.0941 Boehringer Ingelheim Investigational Site
-
Suhl, Alemania
- 1160.26.0959 Boehringer Ingelheim Investigational Site
-
Witten, Alemania
- 1160.26.0937 Boehringer Ingelheim Investigational Site
-
Wuppertal, Alemania
- 1160.26.0966 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bahía Blanca, Argentina
- 1160.26.0523 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1160.26.0524 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1160.26.0533 Boehringer Ingelheim Investigational Site
-
Cipolletti, Argentina
- 1160.26.0526 Boehringer Ingelheim Investigational Site
-
Coronel Suárez, Argentina
- 1160.26.0529 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 1160.26.0531 Boehringer Ingelheim Investigational Site
-
La Plata, Argentina
- 1160.26.0530 Boehringer Ingelheim Investigational Site
-
Mar del Plata, Argentina
- 1160.26.0527 Boehringer Ingelheim Investigational Site
-
Mar del Plata, Argentina
- 1160.26.0532 Boehringer Ingelheim Investigational Site
-
Quilmes, Argentina
- 1160.26.0525 Boehringer Ingelheim Investigational Site
-
Rosario, Argentina
- 1160.26.0521 Boehringer Ingelheim Investigational Site
-
Salta, Argentina
- 1160.26.0528 Boehringer Ingelheim Investigational Site
-
Santa Fe, Argentina
- 1160.26.0522 Boehringer Ingelheim Investigational Site
-
-
-
-
New South Wales
-
Coffs Harbour, New South Wales, Australia
- 1160.26.0508 Boehringer Ingelheim Investigational Site
-
Gosford, New South Wales, Australia
- 1160.26.0510 Boehringer Ingelheim Investigational Site
-
-
Queensland
-
Herston, Queensland, Australia
- 1160.26.0505 Boehringer Ingelheim Investigational Site
-
Milton, Queensland, Australia
- 1160.26.0506 Boehringer Ingelheim Investigational Site
-
-
South Australia
-
Ashford, South Australia, Australia
- 1160.26.0509 Boehringer Ingelheim Investigational Site
-
-
Tasmania
-
Launceston, Tasmania, Australia
- 1160.26.0507 Boehringer Ingelheim Investigational Site
-
-
Victoria
-
Box Hill, Victoria, Australia
- 1160.26.0504 Boehringer Ingelheim Investigational Site
-
Geelong, Victoria, Australia
- 1160.26.0501 Boehringer Ingelheim Investigational Site
-
Parkville, Victoria, Australia
- 1160.26.0502 Boehringer Ingelheim Investigational Site
-
Prahran, Victoria, Australia
- 1160.26.0503 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Graz, Austria
- 1160.26.0543 Boehringer Ingelheim Investigational Site
-
Linz, Austria
- 1160.26.0549 Boehringer Ingelheim Investigational Site
-
Wels, Austria
- 1160.26.0546 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 1160.26.0541 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 1160.26.0542 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 1160.26.0544 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 1160.26.0545 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 1160.26.0547 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 1160.26.0548 Boehringer Ingelheim Investigational Site
-
Wr. Neustadt, Austria
- 1160.26.0550 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Belo Horizonte, Brasil
- 1160.26.550648 Boehringer Ingelheim Investigational Site
-
Blumenau, Brasil
- 1160.26.550654 Boehringer Ingelheim Investigational Site
-
Campinas, Brasil
- 1160.26.550644 Boehringer Ingelheim Investigational Site
-
Curitiba, Brasil
- 1160.26.550650 Boehringer Ingelheim Investigational Site
-
Curitiba, Brasil
- 1160.26.550651 Boehringer Ingelheim Investigational Site
-
Curitiba, Brasil
- 1160.26.550653 Boehringer Ingelheim Investigational Site
-
Goiania, Brasil
- 1160.26.550652 Boehringer Ingelheim Investigational Site
-
Marília, Brasil
- 1160.26.550645 Boehringer Ingelheim Investigational Site
-
São José do Rio Preto, Brasil
- 1160.26.550646 Boehringer Ingelheim Investigational Site
-
São José do Rio Preto, Brasil
- 1160.26.550647 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasil
- 1160.26.550641 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasil
- 1160.26.550642 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasil
- 1160.26.550643 Boehringer Ingelheim Investigational Site
-
Uberaba, Brasil
- 1160.26.550649 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Pleven, Bulgaria
- 1160.26.0620 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0611 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0612 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0613 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0614 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0615 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0616 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0617 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0618 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0622 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0623 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0624 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1160.26.0625 Boehringer Ingelheim Investigational Site
-
Stara Zagora, Bulgaria
- 1160.26.0626 Boehringer Ingelheim Investigational Site
-
Varna, Bulgaria
- 1160.26.0621 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aalst, Bélgica
- 1160.26.0564 Boehringer Ingelheim Investigational Site
-
Antwerpen, Bélgica
- 1160.26.0573 Boehringer Ingelheim Investigational Site
-
Antwerpen, Bélgica
- 1160.26.0575 Boehringer Ingelheim Investigational Site
-
Brasschaat, Bélgica
- 1160.26.0572 Boehringer Ingelheim Investigational Site
-
Brugge, Bélgica
- 1160.26.0577 Boehringer Ingelheim Investigational Site
-
Brussels, Bélgica
- 1160.26.0571 Boehringer Ingelheim Investigational Site
-
Bruxelles, Bélgica
- 1160.26.0581 Boehringer Ingelheim Investigational Site
-
Bruxelles, Bélgica
- 1160.26.0585 Boehringer Ingelheim Investigational Site
-
Bruxelles, Bélgica
- 1160.26.0586 Boehringer Ingelheim Investigational Site
-
Edegem, Bélgica
- 1160.26.0563 Boehringer Ingelheim Investigational Site
-
Genk, Bélgica
- 1160.26.0578 Boehringer Ingelheim Investigational Site
-
Genk, Bélgica
- 1160.26.0587 Boehringer Ingelheim Investigational Site
-
Gent, Bélgica
- 1160.26.0574 Boehringer Ingelheim Investigational Site
-
Gilly, Bélgica
- 1160.26.0588 Boehringer Ingelheim Investigational Site
-
Haine-St.-Paul, Bélgica
- 1160.26.0580 Boehringer Ingelheim Investigational Site
-
Hasselt, Bélgica
- 1160.26.0568 Boehringer Ingelheim Investigational Site
-
Kortrijk, Bélgica
- 1160.26.0569 Boehringer Ingelheim Investigational Site
-
Leuven, Bélgica
- 1160.26.0561 Boehringer Ingelheim Investigational Site
-
Liège, Bélgica
- 1160.26.0579 Boehringer Ingelheim Investigational Site
-
Liège, Bélgica
- 1160.26.0583 Boehringer Ingelheim Investigational Site
-
Mol, Bélgica
- 1160.26.0589 Boehringer Ingelheim Investigational Site
-
Oostende, Bélgica
- 1160.26.0567 Boehringer Ingelheim Investigational Site
-
Roeselare, Bélgica
- 1160.26.0570 Boehringer Ingelheim Investigational Site
-
Tienen, Bélgica
- 1160.26.0566 Boehringer Ingelheim Investigational Site
-
Turnhout, Bélgica
- 1160.26.0562 Boehringer Ingelheim Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá
- 1160.26.0694 Boehringer Ingelheim Investigational Site
-
Calgary, Alberta, Canadá
- 1160.26.0696 Boehringer Ingelheim Investigational Site
-
-
British Columbia
-
Coquitlam, British Columbia, Canadá
- 1160.26.0680 Boehringer Ingelheim Investigational Site
-
Coquitlam, British Columbia, Canadá
- 1160.26.0712 Boehringer Ingelheim Investigational Site
-
Kelowna, British Columbia, Canadá
- 1160.26.0706 Boehringer Ingelheim Investigational Site
-
Nanaimo, British Columbia, Canadá
- 1160.26.0725 Boehringer Ingelheim Investigational Site
-
New Westminster, British Columbia, Canadá
- 1160.26.0691 Boehringer Ingelheim Investigational Site
-
Victoria, British Columbia, Canadá
- 1160.26.0714 Boehringer Ingelheim Investigational Site
-
-
Manitoba
-
Portage la Prairie, Manitoba, Canadá
- 1160.26.0701 Boehringer Ingelheim Investigational Site
-
Winnipeg, Manitoba, Canadá
- 1160.26.0698 Boehringer Ingelheim Investigational Site
-
-
Newfoundland and Labrador
-
Bay Roberts, Newfoundland and Labrador, Canadá
- 1160.26.0707 Boehringer Ingelheim Investigational Site
-
-
Nova Scotia
-
Antigonish, Nova Scotia, Canadá
- 1160.26.0676 Boehringer Ingelheim Investigational Site
-
Halifax, Nova Scotia, Canadá
- 1160.26.0703 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Ajax, Ontario, Canadá
- 1160.26.0679 Boehringer Ingelheim Investigational Site
-
Brampton, Ontario, Canadá
- 1160.26.0677 Boehringer Ingelheim Investigational Site
-
Burlington, Ontario, Canadá
- 1160.26.0674 Boehringer Ingelheim Investigational Site
-
Cambridge, Ontario, Canadá
- 1160.26.0702 Boehringer Ingelheim Investigational Site
-
Cambridge, Ontario, Canadá
- 1160.26.0720 Boehringer Ingelheim Investigational Site
-
Etobicoke, Ontario, Canadá
- 1160.26.0671 Clinical Research & Diagnostic Solutions Inc.
-
Grimsby, Ontario, Canadá
- 1160.26.0692 Boehringer Ingelheim Investigational Site
-
Hamilton, Ontario, Canadá
- 1160.26.0685 Boehringer Ingelheim Investigational Site
-
Hamilton, Ontario, Canadá
- 1160.26.0697 Boehringer Ingelheim Investigational Site
-
Hamilton, Ontario, Canadá
- 1160.26.0710 Boehringer Ingelheim Investigational Site
-
Hamilton, Ontario, Canadá
- 1160.26.0719 Boehringer Ingelheim Investigational Site
-
Hamilton, Ontario, Canadá
- 1160.26.0721 Boehringer Ingelheim Investigational Site
-
Kitchener, Ontario, Canadá
- 1160.26.0689 Boehringer Ingelheim Investigational Site
-
Mississauga, Ontario, Canadá
- 1160.26.0695 Boehringer Ingelheim Investigational Site
-
Mississauga, Ontario, Canadá
- 1160.26.0708 Boehringer Ingelheim Investigational Site
-
Mississauga, Ontario, Canadá
- 1160.26.0724 Boehringer Ingelheim Investigational Site
-
Newmarket, Ontario, Canadá
- 1160.26.0688 Boehringer Ingelheim Investigational Site
-
Oshawa, Ontario, Canadá
- 1160.26.0672 Boehringer Ingelheim Investigational Site
-
Ottawa, Ontario, Canadá
- 1160.26.0687 Boehringer Ingelheim Investigational Site
-
Scarborough, Ontario, Canadá
- 1160.26.0723 Boehringer Ingelheim Investigational Site
-
Sudbury, Ontario, Canadá
- 1160.26.0715 Boehringer Ingelheim Investigational Site
-
Thunder Bay, Ontario, Canadá
- 1160.26.0690 Boehringer Ingelheim Investigational Site
-
Toronto, Ontario, Canadá
- 1160.26.0684 Boehringer Ingelheim Investigational Site
-
Toronto, Ontario, Canadá
- 1160.26.0718 Boehringer Ingelheim Investigational Site
-
Waterloo, Ontario, Canadá
- 1160.26.0711 Boehringer Ingelheim Investigational Site
-
Windsor, Ontario, Canadá
- 1160.26.0686 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Longueuil, Quebec, Canadá
- 1160.26.0693 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canadá
- 1160.26.0681 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canadá
- 1160.26.0683 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canadá
- 1160.26.0705 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canadá
- 1160.26.0709 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canadá
- 1160.26.0716 Boehringer Ingelheim Investigational Site
-
Quebec City, Quebec, Canadá
- 1160.26.0717 Boehringer Ingelheim Investigational Site
-
Saint George-de-Beauce, Quebec, Canadá
- 1160.26.0713 Boehringer Ingelheim Investigational Site
-
Saint Jerome, Quebec, Canadá
- 1160.26.0704 Boehringer Ingelheim Investigational Site
-
St. Charles-Borromee, Quebec, Canadá
- 1160.26.0699 Boehringer Ingelheim Investigational Site
-
St. Hyacinthe, Quebec, Canadá
- 1160.26.0675 Boehringer Ingelheim Investigational Site
-
Ste-Foy, Quebec, Canadá
- 1160.26.0700 Boehringer Ingelheim Investigational Site
-
Terrebonne (Lachenaie), Quebec, Canadá
- 1160.26.0682 Boehringer Ingelheim Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá
- 1160.26.0673 Boehringer Ingelheim Investigational Site
-
Saskatoon, Saskatchewan, Canadá
- 1160.26.0678 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brno, Chequia
- 1160.26.0815 Boehringer Ingelheim Investigational Site
-
Brno, Chequia
- 1160.26.0816 Boehringer Ingelheim Investigational Site
-
Ostrava 1, Chequia
- 1160.26.0820 Boehringer Ingelheim Investigational Site
-
Pardubice, Chequia
- 1160.26.0818 Boehringer Ingelheim Investigational Site
-
Plzen-Bory, Chequia
- 1160.26.0814 Boehringer Ingelheim Investigational Site
-
Pragha 9, Chequia
- 1160.26.0813 Boehringer Ingelheim Investigational Site
-
Prague 5, Chequia
- 1160.26.0811 Boehringer Ingelheim Investigational Site
-
Praha 6, Chequia
- 1160.26.0812 Boehringer Ingelheim Investigational Site
-
Pribram, Chequia
- 1160.26.0817 Boehringer Ingelheim Investigational Site
-
Usti nad Orlici, Chequia
- 1160.26.0819 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bogotá, Colombia
- 1160.26.0801 Boehringer Ingelheim Investigational Site
-
Bogotá, Colombia
- 1160.26.0802 Boehringer Ingelheim Investigational Site
-
Bogotá, Colombia
- 1160.26.0803 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Busan, Corea, república de
- 1160.26.1585 Boehringer Ingelheim Investigational Site
-
Chungchungnam-Do, Corea, república de
- 1160.26.1586 Boehringer Ingelheim Investigational Site
-
Daegu, Corea, república de
- 1160.26.1584 Boehringer Ingelheim Investigational Site
-
Daegu, Corea, república de
- 1160.26.1591 Boehringer Ingelheim Investigational Site
-
Gwangju, Corea, república de
- 1160.26.1590 Boehringer Ingelheim Investigational Site
-
Incheon, Corea, república de
- 1160.26.1581 Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de
- 1160.26.1582 Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de
- 1160.26.1583 Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de
- 1160.26.1588 Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de
- 1160.26.1589 Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de
- 1160.26.1592 Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de
- 1160.26.1593 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aalborg, Dinamarca
- 1160.26.0837 Boehringer Ingelheim Investigational Site
-
Aarhus C, Dinamarca
- 1160.26.0835 Boehringer Ingelheim Investigational Site
-
Frederikssund, Dinamarca
- 1160.26.0838 Boehringer Ingelheim Investigational Site
-
Helsingør, Dinamarca
- 1160.26.0833 Boehringer Ingelheim Investigational Site
-
Herlev, Dinamarca
- 1160.26.0834 Boehringer Ingelheim Investigational Site
-
Horsens, Dinamarca
- 1160.26.0841 Boehringer Ingelheim Investigational Site
-
Hvidovre, Dinamarca
- 1160.26.0832 Boehringer Ingelheim Investigational Site
-
Køge, Dinamarca
- 1160.26.0840 Boehringer Ingelheim Investigational Site
-
Odense, Dinamarca
- 1160.26.0831 Boehringer Ingelheim Investigational Site
-
Roskilde, Dinamarca
- 1160.26.0839 Boehringer Ingelheim Investigational Site
-
Svendborg, Dinamarca
- 1160.26.0836 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Banska Bystrica, Eslovaquia
- 1160.26.1548 Boehringer Ingelheim Investigational Site
-
Bratislava, Eslovaquia
- 1160.26.1541 Boehringer Ingelheim Investigational Site
-
Bratislava, Eslovaquia
- 1160.26.1542 Boehringer Ingelheim Investigational Site
-
Bratislava, Eslovaquia
- 1160.26.1543 Boehringer Ingelheim Investigational Site
-
Bratislava, Eslovaquia
- 1160.26.1544 Boehringer Ingelheim Investigational Site
-
Bratislava, Eslovaquia
- 1160.26.1545 Boehringer Ingelheim Investigational Site
-
Bratislava, Eslovaquia
- 1160.26.1546 Boehringer Ingelheim Investigational Site
-
Kosice, Eslovaquia
- 1160.26.1549 Boehringer Ingelheim Investigational Site
-
Kosice, Eslovaquia
- 1160.26.1550 Boehringer Ingelheim Investigational Site
-
Zilina, Eslovaquia
- 1160.26.1547 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, España
- 1160.26.1601 Boehringer Ingelheim Investigational Site
-
Cadiz, España
- 1160.26.1606 Boehringer Ingelheim Investigational Site
-
Fuenlabrada (Madrid), España
- 1160.26.1607 Boehringer Ingelheim Investigational Site
-
Leganés, Madrid, España
- 1160.26.1604 Boehringer Ingelheim Investigational Site
-
Madrid, España
- 1160.26.1603 Boehringer Ingelheim Investigational Site
-
Madrid, España
- 1160.26.1608 Boehringer Ingelheim Investigational Site
-
Madrid-San Lorenzo Del Escorial, España
- 1160.26.1609 Boehringer Ingelheim Investigational Site
-
Móstoles (Madrid), España
- 1160.26.1605 Boehringer Ingelheim Investigational Site
-
Sabadell, España
- 1160.26.1602 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos
- 1160.26.0009 Boehringer Ingelheim Investigational Site
-
Birmingham, Alabama, Estados Unidos
- 1160.26.0046 Boehringer Ingelheim Investigational Site
-
Birmingham, Alabama, Estados Unidos
- 1160.26.0057 Boehringer Ingelheim Investigational Site
-
Birmingham, Alabama, Estados Unidos
- 1160.26.0211 Boehringer Ingelheim Investigational Site
-
Huntsville, Alabama, Estados Unidos
- 1160.26.0206 Boehringer Ingelheim Investigational Site
-
Mobile, Alabama, Estados Unidos
- 1160.26.0115 Boehringer Ingelheim Investigational Site
-
-
Arizona
-
Lake Havasu City, Arizona, Estados Unidos
- 1160.26.0104 Boehringer Ingelheim Investigational Site
-
Peoria, Arizona, Estados Unidos
- 1160.26.0304 Boehringer Ingelheim Investigational Site
-
Tucson, Arizona, Estados Unidos
- 1160.26.0185 Boehringer Ingelheim Investigational Site
-
Tucson, Arizona, Estados Unidos
- 1160.26.0305 Boehringer Ingelheim Investigational Site
-
-
Arkansas
-
Hot Springs, Arkansas, Estados Unidos
- 1160.26.0038 Boehringer Ingelheim Investigational Site
-
Jonesboro, Arkansas, Estados Unidos
- 1160.26.0302 Boehringer Ingelheim Investigational Site
-
Little Rock, Arkansas, Estados Unidos
- 1160.26.0121 Boehringer Ingelheim Investigational Site
-
Little Rock, Arkansas, Estados Unidos
- 1160.26.0191 Boehringer Ingelheim Investigational Site
-
Little Rock, Arkansas, Estados Unidos
- 1160.26.0204 Boehringer Ingelheim Investigational Site
-
Little Rock, Arkansas, Estados Unidos
- 1160.26.0213 Boehringer Ingelheim Investigational Site
-
Little Rock, Arkansas, Estados Unidos
- 1160.26.0455 Boehringer Ingelheim Investigational Site
-
-
California
-
Anaheim, California, Estados Unidos
- 1160.26.0388 Boehringer Ingelheim Investigational Site
-
Carmichael, California, Estados Unidos
- 1160.26.0441 Boehringer Ingelheim Investigational Site
-
French Camp, California, Estados Unidos
- 1160.26.0145 Boehringer Ingelheim Investigational Site
-
Fullerton, California, Estados Unidos
- 1160.26.0333 Boehringer Ingelheim Investigational Site
-
La Jolla, California, Estados Unidos
- 1160.26.0384 Boehringer Ingelheim Investigational Site
-
La Mesa, California, Estados Unidos
- 1160.26.0091 Boehringer Ingelheim Investigational Site
-
Lancaster, California, Estados Unidos
- 1160.26.0246 Boehringer Ingelheim Investigational Site
-
Larkspur, California, Estados Unidos
- 1160.26.0345 Boehringer Ingelheim Investigational Site
-
Loma Linda, California, Estados Unidos
- 1160.26.0217 Boehringer Ingelheim Investigational Site
-
Los Angeles, California, Estados Unidos
- 1160.26.0059 Boehringer Ingelheim Investigational Site
-
Los Angeles, California, Estados Unidos
- 1160.26.0088 Boehringer Ingelheim Investigational Site
-
Los Angeles, California, Estados Unidos
- 1160.26.0337 Boehringer Ingelheim Investigational Site
-
Mather, California, Estados Unidos
- 1160.26.0326 Boehringer Ingelheim Investigational Site
-
Merced, California, Estados Unidos
- 1160.26.0070 Boehringer Ingelheim Investigational Site
-
Oakland, California, Estados Unidos
- 1160.26.0349 Boehringer Ingelheim Investigational Site
-
Oceanside, California, Estados Unidos
- 1160.26.0016 Boehringer Ingelheim Investigational Site
-
Palm Springs, California, Estados Unidos
- 1160.26.0087 Boehringer Ingelheim Investigational Site
-
Pasadena, California, Estados Unidos
- 1160.26.0459 Boehringer Ingelheim Investigational Site
-
Redondo Beach, California, Estados Unidos
- 1160.26.0216 Boehringer Ingelheim Investigational Site
-
Riverside, California, Estados Unidos
- 1160.26.0135 Boehringer Ingelheim Investigational Site
-
Sacramento, California, Estados Unidos
- 1160.26.0162 Boehringer Ingelheim Investigational Site
-
Sacramento, California, Estados Unidos
- 1160.26.0300 Boehringer Ingelheim Investigational Site
-
Sacramento, California, Estados Unidos
- 1160.26.0371 Boehringer Ingelheim Investigational Site
-
San Diego, California, Estados Unidos
- 1160.26.0116 Boehringer Ingelheim Investigational Site
-
San Diego, California, Estados Unidos
- 1160.26.0148 Boehringer Ingelheim Investigational Site
-
San Diego, California, Estados Unidos
- 1160.26.0270 Boehringer Ingelheim Investigational Site
-
San Diego, California, Estados Unidos
- 1160.26.0284 Boehringer Ingelheim Investigational Site
-
Santa Ana, California, Estados Unidos
- 1160.26.0351 Boehringer Ingelheim Investigational Site
-
Santa Rosa, California, Estados Unidos
- 1160.26.0043 Boehringer Ingelheim Investigational Site
-
Sylmar, California, Estados Unidos
- 1160.26.0462 Boehringer Ingelheim Investigational Site
-
Torrance, California, Estados Unidos
- 1160.26.0276 Boehringer Ingelheim Investigational Site
-
Walnut Creek, California, Estados Unidos
- 1160.26.0379 Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos
- 1160.26.0419 Boehringer Ingelheim Investigational Site
-
Colorado Springs, Colorado, Estados Unidos
- 1160.26.0321 Boehringer Ingelheim Investigational Site
-
Colorado Springs, Colorado, Estados Unidos
- 1160.26.0449 Boehringer Ingelheim Investigational Site
-
Denver, Colorado, Estados Unidos
- 1160.26.0360 Boehringer Ingelheim Investigational Site
-
Denver, Colorado, Estados Unidos
- 1160.26.0413 Boehringer Ingelheim Investigational Site
-
Fort Collins, Colorado, Estados Unidos
- 1160.26.0362 Boehringer Ingelheim Investigational Site
-
Greeley, Colorado, Estados Unidos
- 1160.26.0399 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos
- 1160.26.0058 Boehringer Ingelheim Investigational Site
-
Bridgeport, Connecticut, Estados Unidos
- 1160.26.0241 Boehringer Ingelheim Investigational Site
-
Bridgeport, Connecticut, Estados Unidos
- 1160.26.0278 Boehringer Ingelheim Investigational Site
-
Fairfield, Connecticut, Estados Unidos
- 1160.26.0085 Boehringer Ingelheim Investigational Site
-
Guilford, Connecticut, Estados Unidos
- 1160.26.0482 Boehringer Ingelheim Investigational Site
-
-
Delaware
-
Newark, Delaware, Estados Unidos
- 1160.26.0366 Boehringer Ingelheim Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos
- 1160.26.0343 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Atlantis, Florida, Estados Unidos
- 1160.26.0022 Boehringer Ingelheim Investigational Site
-
Boynton Beach, Florida, Estados Unidos
- 1160.26.0382 Boehringer Ingelheim Investigational Site
-
Brandon, Florida, Estados Unidos
- 1160.26.0056 Boehringer Ingelheim Investigational Site
-
Clearwater, Florida, Estados Unidos
- 1160.26.0105 Boehringer Ingelheim Investigational Site
-
Clearwater, Florida, Estados Unidos
- 1160.26.0296 Boehringer Ingelheim Investigational Site
-
Clearwater, Florida, Estados Unidos
- 1160.26.0429 Boehringer Ingelheim Investigational Site
-
Daytona Beach, Florida, Estados Unidos
- 1160.26.0376 Boehringer Ingelheim Investigational Site
-
Deerfield Beach, Florida, Estados Unidos
- 1160.26.0411 Boehringer Ingelheim Investigational Site
-
Fort Myers, Florida, Estados Unidos
- 1160.26.0074 Boehringer Ingelheim Investigational Site
-
Gainesville, Florida, Estados Unidos
- 1160.26.0239 Boehringer Ingelheim Investigational Site
-
Hollywood, Florida, Estados Unidos
- 1160.26.0260 Boehringer Ingelheim Investigational Site
-
Hollywood, Florida, Estados Unidos
- 1160.26.0265 Boehringer Ingelheim Investigational Site
-
Inverness, Florida, Estados Unidos
- 1160.26.0100 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Estados Unidos
- 1160.26.0033 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Estados Unidos
- 1160.26.0089 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Estados Unidos
- 1160.26.0232 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Estados Unidos
- 1160.26.0240 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Estados Unidos
- 1160.26.0427 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Estados Unidos
- 1160.26.0464 Boehringer Ingelheim Investigational Site
-
Jacksonville Beach, Florida, Estados Unidos
- 1160.26.0209 Boehringer Ingelheim Investigational Site
-
Lakeland, Florida, Estados Unidos
- 1160.26.0012 Boehringer Ingelheim Investigational Site
-
Melbourne, Florida, Estados Unidos
- 1160.26.0259 Boehringer Ingelheim Investigational Site
-
Melbourne, Florida, Estados Unidos
- 1160.26.0358 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Estados Unidos
- 1160.26.0034 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Estados Unidos
- 1160.26.0199 Boehringer Ingelheim Investigational Site
-
Orlando, Florida, Estados Unidos
- 1160.26.0227 Boehringer Ingelheim Investigational Site
-
Ormond Beach, Florida, Estados Unidos
- 1160.26.0095 Boehringer Ingelheim Investigational Site
-
Pensacola, Florida, Estados Unidos
- 1160.26.0037 Boehringer Ingelheim Investigational Site
-
Pensacola, Florida, Estados Unidos
- 1160.26.0076 Boehringer Ingelheim Investigational Site
-
Pensacola, Florida, Estados Unidos
- 1160.26.0081 Boehringer Ingelheim Investigational Site
-
Pensacola, Florida, Estados Unidos
- 1160.26.0111 Boehringer Ingelheim Investigational Site
-
Port Charlotte, Florida, Estados Unidos
- 1160.26.0137 Boehringer Ingelheim Investigational Site
-
Port Charlotte, Florida, Estados Unidos
- 1160.26.0389 Boehringer Ingelheim Investigational Site
-
Port Charlotte, Florida, Estados Unidos
- 1160.26.0417 Boehringer Ingelheim Investigational Site
-
Rockledge, Florida, Estados Unidos
- 1160.26.0332 Boehringer Ingelheim Investigational Site
-
Safety Harbor, Florida, Estados Unidos
- 1160.26.0226 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Florida, Estados Unidos
- 1160.26.0015 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Florida, Estados Unidos
- 1160.26.0339 Boehringer Ingelheim Investigational Site
-
Sarasota, Florida, Estados Unidos
- 1160.26.0031 Boehringer Ingelheim Investigational Site
-
Sarasota, Florida, Estados Unidos
- 1160.26.0385 Boehringer Ingelheim Investigational Site
-
Stuart, Florida, Estados Unidos
- 1160.26.0010 Boehringer Ingelheim Investigational Site
-
Tamarac, Florida, Estados Unidos
- 1160.26.0327 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Estados Unidos
- 1160.26.0271 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Estados Unidos
- 1160.26.0328 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Estados Unidos
- 1160.26.0381 Boehringer Ingelheim Investigational Site
-
Vero Beach, Florida, Estados Unidos
- 1160.26.0019 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos
- 1160.26.0159 Boehringer Ingelheim Investigational Site
-
Atlanta, Georgia, Estados Unidos
- 1160.26.0283 Boehringer Ingelheim Investigational Site
-
Atlanta, Georgia, Estados Unidos
- 1160.26.0338 Boehringer Ingelheim Investigational Site
-
Augusta, Georgia, Estados Unidos
- 1160.26.0021 Boehringer Ingelheim Investigational Site
-
Augusta, Georgia, Estados Unidos
- 1160.26.0319 Boehringer Ingelheim Investigational Site
-
Blue Ridge, Georgia, Estados Unidos
- 1160.26.0092 Boehringer Ingelheim Investigational Site
-
Conyers, Georgia, Estados Unidos
- 1160.26.0161 Boehringer Ingelheim Investigational Site
-
-
Idaho
-
Coeur d'Alene, Idaho, Estados Unidos
- 1160.26.0026 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Berwyn, Illinois, Estados Unidos
- 1160.26.0218 Boehringer Ingelheim Investigational Site
-
Chicago, Illinois, Estados Unidos
- 1160.26.0184 Boehringer Ingelheim Investigational Site
-
Chicago, Illinois, Estados Unidos
- 1160.26.0233 Boehringer Ingelheim Investigational Site
-
Chicago, Illinois, Estados Unidos
- 1160.26.0324 Boehringer Ingelheim Investigational Site
-
Chicago, Illinois, Estados Unidos
- 1160.26.0457 Boehringer Ingelheim Investigational Site
-
Evanston, Illinois, Estados Unidos
- 1160.26.0237 Boehringer Ingelheim Investigational Site
-
Glenview, Illinois, Estados Unidos
- 1160.26.0236 Boehringer Ingelheim Investigational Site
-
Hines, Illinois, Estados Unidos
- 1160.26.0396 Boehringer Ingelheim Investigational Site
-
Maywood, Illinois, Estados Unidos
- 1160.26.0438 Boehringer Ingelheim Investigational Site
-
Melrose Park, Illinois, Estados Unidos
- 1160.26.0331 Boehringer Ingelheim Investigational Site
-
Normal, Illinois, Estados Unidos
- 1160.26.0364 Boehringer Ingelheim Investigational Site
-
North Chicago, Illinois, Estados Unidos
- 1160.26.0109 Boehringer Ingelheim Investigational Site
-
Oak Lawn, Illinois, Estados Unidos
- 1160.26.0152 Boehringer Ingelheim Investigational Site
-
Rockford, Illinois, Estados Unidos
- 1160.26.0198 Boehringer Ingelheim Investigational Site
-
Winfield, Illinois, Estados Unidos
- 1160.26.0433 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Evansville, Indiana, Estados Unidos
- 1160.26.0041 Boehringer Ingelheim Investigational Site
-
Fort Wayne, Indiana, Estados Unidos
- 1160.26.0377 Boehringer Ingelheim Investigational Site
-
Indianapolis, Indiana, Estados Unidos
- 1160.26.0288 Boehringer Ingelheim Investigational Site
-
Indianapolis, Indiana, Estados Unidos
- 1160.26.0352 Boehringer Ingelheim Investigational Site
-
Indianapolis, Indiana, Estados Unidos
- 1160.26.0436 Boehringer Ingelheim Investigational Site
-
Jeffersonville, Indiana, Estados Unidos
- 1160.26.0028 Boehringer Ingelheim Investigational Site
-
South Bend, Indiana, Estados Unidos
- 1160.26.0235 Boehringer Ingelheim Investigational Site
-
-
Iowa
-
Dubuque, Iowa, Estados Unidos
- 1160.26.0268 Boehringer Ingelheim Investigational Site
-
West Des Moines, Iowa, Estados Unidos
- 1160.26.0001 Boehringer Ingelheim Investigational Site
-
West Des Moines, Iowa, Estados Unidos
- 1160.26.0189 Boehringer Ingelheim Investigational Site
-
West Des Moines, Iowa, Estados Unidos
- 1160.26.0357 Boehringer Ingelheim Investigational Site
-
-
Kansas
-
Wichita, Kansas, Estados Unidos
- 1160.26.0354 Boehringer Ingelheim Investigational Site
-
-
Kentucky
-
Bowling Green, Kentucky, Estados Unidos
- 1160.26.0077 Boehringer Ingelheim Investigational Site
-
Crestview Hills, Kentucky, Estados Unidos
- 1160.26.0138 Boehringer Ingelheim Investigational Site
-
Lexington, Kentucky, Estados Unidos
- 1160.26.0422 Boehringer Ingelheim Investigational Site
-
Louisville, Kentucky, Estados Unidos
- 1160.26.0178 Boehringer Ingelheim Investigational Site
-
Louisville, Kentucky, Estados Unidos
- 1160.26.0397 Boehringer Ingelheim Investigational Site
-
Owensboro, Kentucky, Estados Unidos
- 1160.26.0310 Boehringer Ingelheim Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos
- 1160.26.0011 Boehringer Ingelheim Investigational Site
-
Baton Rouge, Louisiana, Estados Unidos
- 1160.26.0144 Boehringer Ingelheim Investigational Site
-
Baton Rouge, Louisiana, Estados Unidos
- 1160.26.0404 Boehringer Ingelheim Investigational Site
-
Covington, Louisiana, Estados Unidos
- 1160.26.0093 Boehringer Ingelheim Investigational Site
-
Lacombe, Louisiana, Estados Unidos
- 1160.26.0340 Boehringer Ingelheim Investigational Site
-
Lafayette, Louisiana, Estados Unidos
- 1160.26.0018 Boehringer Ingelheim Investigational Site
-
Lafayette, Louisiana, Estados Unidos
- 1160.26.0391 Boehringer Ingelheim Investigational Site
-
Morgan City, Louisiana, Estados Unidos
- 1160.26.0252 Boehringer Ingelheim Investigational Site
-
New Iberia, Louisiana, Estados Unidos
- 1160.26.0132 Boehringer Ingelheim Investigational Site
-
New Orleans, Louisiana, Estados Unidos
- 1160.26.0299 Tulane University School Of Medicine
-
Shreveport, Louisiana, Estados Unidos
- 1160.26.0048 Boehringer Ingelheim Investigational Site
-
-
Maine
-
Auburn, Maine, Estados Unidos
- 1160.26.0096 Boehringer Ingelheim Investigational Site
-
Scarborough, Maine, Estados Unidos
- 1160.26.0068 Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos
- 1160.26.0114 Boehringer Ingelheim Investigational Site
-
Annapolis, Maryland, Estados Unidos
- 1160.26.0164 Boehringer Ingelheim Investigational Site
-
Baltimore, Maryland, Estados Unidos
- 1160.26.0023 Boehringer Ingelheim Investigational Site
-
Baltimore, Maryland, Estados Unidos
- 1160.26.0047 Boehringer Ingelheim Investigational Site
-
Baltimore, Maryland, Estados Unidos
- 1160.26.0079 Boehringer Ingelheim Investigational Site
-
Baltimore, Maryland, Estados Unidos
- 1160.26.0186 Boehringer Ingelheim Investigational Site
-
Baltimore, Maryland, Estados Unidos
- 1160.26.0194 Boehringer Ingelheim Investigational Site
-
Bel Air, Maryland, Estados Unidos
- 1160.26.0255 Boehringer Ingelheim Investigational Site
-
Columbia, Maryland, Estados Unidos
- 1160.26.0398 Boehringer Ingelheim Investigational Site
-
Rockville, Maryland, Estados Unidos
- 1160.26.0177 Boehringer Ingelheim Investigational Site
-
Salisbury, Maryland, Estados Unidos
- 1160.26.0073 Boehringer Ingelheim Investigational Site
-
Salisbury, Maryland, Estados Unidos
- 1160.26.0207 Boehringer Ingelheim Investigational Site
-
Takoma Park, Maryland, Estados Unidos
- 1160.26.0196 Boehringer Ingelheim Investigational Site
-
Towson, Maryland, Estados Unidos
- 1160.26.0187 Boehringer Ingelheim Investigational Site
-
Westminster, Maryland, Estados Unidos
- 1160.26.0052 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Ayer, Massachusetts, Estados Unidos
- 1160.26.0042 Boehringer Ingelheim Investigational Site
-
Boston, Massachusetts, Estados Unidos
- 1160.26.0401 Boehringer Ingelheim Investigational Site
-
East Bridgewater, Massachusetts, Estados Unidos
- 1160.26.0160 Boehringer Ingelheim Investigational Site
-
Haverhill, Massachusetts, Estados Unidos
- 1160.26.0443 Boehringer Ingelheim Investigational Site
-
Haverhill, Massachusetts, Estados Unidos
- 1160.26.0452 Boehringer Ingelheim Investigational Site
-
Natick, Massachusetts, Estados Unidos
- 1160.26.0029 Boehringer Ingelheim Investigational Site
-
Newtown, Massachusetts, Estados Unidos
- 1160.26.0446 Boehringer Ingelheim Investigational Site
-
North Dartmouth, Massachusetts, Estados Unidos
- 1160.26.0003 Boehringer Ingelheim Investigational Site
-
Northborough, Massachusetts, Estados Unidos
- 1160.26.0470 Boehringer Ingelheim Investigational Site
-
Worcester, Massachusetts, Estados Unidos
- 1160.26.0308 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Bloomfield Hills, Michigan, Estados Unidos
- 1160.26.0141 Boehringer Ingelheim Investigational Site
-
Detroit, Michigan, Estados Unidos
- 1160.26.0225 Boehringer Ingelheim Investigational Site
-
Grand Blanc, Michigan, Estados Unidos
- 1160.26.0154 Boehringer Ingelheim Investigational Site
-
Grand Rapids, Michigan, Estados Unidos
- 1160.26.0030 Boehringer Ingelheim Investigational Site
-
Kalamazoo, Michigan, Estados Unidos
- 1160.26.0171 Boehringer Ingelheim Investigational Site
-
Lapeer, Michigan, Estados Unidos
- 1160.26.0205 Boehringer Ingelheim Investigational Site
-
Muskegon, Michigan, Estados Unidos
- 1160.26.0279 Boehringer Ingelheim Investigational Site
-
Petoskey, Michigan, Estados Unidos
- 1160.26.0445 Boehringer Ingelheim Investigational Site
-
Rochester Hills, Michigan, Estados Unidos
- 1160.26.0274 Boehringer Ingelheim Investigational Site
-
Saginaw, Michigan, Estados Unidos
- 1160.26.0165 Boehringer Ingelheim Investigational Site
-
Troy, Michigan, Estados Unidos
- 1160.26.0020 Boehringer Ingelheim Investigational Site
-
Ypsilanti, Michigan, Estados Unidos
- 1160.26.0188 Boehringer Ingelheim Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos
- 1160.26.0131 Boehringer Ingelheim Investigational Site
-
Minneapolis, Minnesota, Estados Unidos
- 1160.26.0421 Boehringer Ingelheim Investigational Site
-
Robbinsdale, Minnesota, Estados Unidos
- 1160.26.0202 Boehringer Ingelheim Investigational Site
-
Saint Paul, Minnesota, Estados Unidos
- 1160.26.0101 Boehringer Ingelheim Investigational Site
-
-
Mississippi
-
Gulfport, Mississippi, Estados Unidos
- 1160.26.0086 Boehringer Ingelheim Investigational Site
-
Tupelo, Mississippi, Estados Unidos
- 1160.26.0119 Boehringer Ingelheim Investigational Site
-
-
Missouri
-
Columbia, Missouri, Estados Unidos
- 1160.26.0055 Boehringer Ingelheim Investigational Site
-
Columbia, Missouri, Estados Unidos
- 1160.26.0172 Boehringer Ingelheim Investigational Site
-
Kansas City, Missouri, Estados Unidos
- 1160.26.0257 Boehringer Ingelheim Investigational Site
-
Kansas City, Missouri, Estados Unidos
- 1160.26.0266 Boehringer Ingelheim Investigational Site
-
Saint Charles, Missouri, Estados Unidos
- 1160.26.0336 Boehringer Ingelheim Investigational Site
-
Saint Louis, Missouri, Estados Unidos
- 1160.26.0249 Boehringer Ingelheim Investigational Site
-
-
Montana
-
Kalispell, Montana, Estados Unidos
- 1160.26.0027 Boehringer Ingelheim Investigational Site
-
-
Nebraska
-
Alliance, Nebraska, Estados Unidos
- 1160.26.0128 Boehringer Ingelheim Investigational Site
-
Omaha, Nebraska, Estados Unidos
- 1160.26.0110 Boehringer Ingelheim Investigational Site
-
Papillion, Nebraska, Estados Unidos
- 1160.26.0355 Boehringer Ingelheim Investigational Site
-
-
Nevada
-
Henderson, Nevada, Estados Unidos
- 1160.26.0346 Boehringer Ingelheim Investigational Site
-
Las Vegas, Nevada, Estados Unidos
- 1160.26.0066 Boehringer Ingelheim Investigational Site
-
Las Vegas, Nevada, Estados Unidos
- 1160.26.0174 Boehringer Ingelheim Investigational Site
-
Las Vegas, Nevada, Estados Unidos
- 1160.26.0430 Boehringer Ingelheim Investigational Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos
- 1160.26.0190 Boehringer Ingelheim Investigational Site
-
-
New Jersey
-
Browns Mills, New Jersey, Estados Unidos
- 1160.26.0142 Boehringer Ingelheim Investigational Site
-
Cherry Hill, New Jersey, Estados Unidos
- 1160.26.0125 Boehringer Ingelheim Investigational Site
-
Elmer, New Jersey, Estados Unidos
- 1160.26.0432 Boehringer Ingelheim Investigational Site
-
Englewood, New Jersey, Estados Unidos
- 1160.26.0448 Boehringer Ingelheim Investigational Site
-
Flemington, New Jersey, Estados Unidos
- 1160.26.0248 Boehringer Ingelheim Investigational Site
-
Haddon Heights, New Jersey, Estados Unidos
- 1160.26.0244 Boehringer Ingelheim Investigational Site
-
New Brunswick, New Jersey, Estados Unidos
- 1160.26.0243 Boehringer Ingelheim Investigational Site
-
Oakland, New Jersey, Estados Unidos
- 1160.26.0478 Boehringer Ingelheim Investigational Site
-
Ocean City, New Jersey, Estados Unidos
- 1160.26.0392 Boehringer Ingelheim Investigational Site
-
Paterson, New Jersey, Estados Unidos
- 1160.26.0472 Boehringer Ingelheim Investigational Site
-
Voorhees, New Jersey, Estados Unidos
- 1160.26.0221 Boehringer Ingelheim Investigational Site
-
Westwood, New Jersey, Estados Unidos
- 1160.26.0254 Boehringer Ingelheim Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos
- 1160.26.0127 Boehringer Ingelheim Investigational Site
-
Albuquerque, New Mexico, Estados Unidos
- 1160.26.0423 Boehringer Ingelheim Investigational Site
-
-
New York
-
Albany, New York, Estados Unidos
- 1160.26.0476 Boehringer Ingelheim Investigational Site
-
Bronx, New York, Estados Unidos
- 1160.26.0113 Boehringer Ingelheim Investigational Site
-
Bronx, New York, Estados Unidos
- 1160.26.0281 Boehringer Ingelheim Investigational Site
-
Buffalo, New York, Estados Unidos
- 1160.26.0063 Boehringer Ingelheim Investigational Site
-
Cortlandt Manor, New York, Estados Unidos
- 1160.26.0044 Boehringer Ingelheim Investigational Site
-
Flushing, New York, Estados Unidos
- 1160.26.0373 Boehringer Ingelheim Investigational Site
-
Garden City, New York, Estados Unidos
- 1160.26.0045 Boehringer Ingelheim Investigational Site
-
Kingston, New York, Estados Unidos
- 1160.26.0251 Boehringer Ingelheim Investigational Site
-
Mineola, New York, Estados Unidos
- 1160.26.0229 Boehringer Ingelheim Investigational Site
-
Mineola, New York, Estados Unidos
- 1160.26.0451 Boehringer Ingelheim Investigational Site
-
New Hyde Park, New York, Estados Unidos
- 1160.26.0090 Boehringer Ingelheim Investigational Site
-
New Rochelle, New York, Estados Unidos
- 1160.26.0183 Boehringer Ingelheim Investigational Site
-
New York, New York, Estados Unidos
- 1160.26.0316 Boehringer Ingelheim Investigational Site
-
North Massapequa, New York, Estados Unidos
- 1160.26.0146 Boehringer Ingelheim Investigational Site
-
Northport, New York, Estados Unidos
- 1160.26.0210 Boehringer Ingelheim Investigational Site
-
Poughkeepsie, New York, Estados Unidos
- 1160.26.0075 Boehringer Ingelheim Investigational Site
-
Rochester, New York, Estados Unidos
- 1160.26.0197 Boehringer Ingelheim Investigational Site
-
Rochester, New York, Estados Unidos
- 1160.26.0320 Boehringer Ingelheim Investigational Site
-
Scarsdale, New York, Estados Unidos
- 1160.26.0064 Boehringer Ingelheim Investigational Site
-
Troy, New York, Estados Unidos
- 1160.26.0414 Boehringer Ingelheim Investigational Site
-
Watertown, New York, Estados Unidos
- 1160.26.0356 Boehringer Ingelheim Investigational Site
-
Williamsville, New York, Estados Unidos
- 1160.26.0039 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos
- 1160.26.0353 Boehringer Ingelheim Investigational Site
-
Charlotte, North Carolina, Estados Unidos
- 1160.26.0080 Boehringer Ingelheim Investigational Site
-
Charlotte, North Carolina, Estados Unidos
- 1160.26.0412 Boehringer Ingelheim Investigational Site
-
Gastonia, North Carolina, Estados Unidos
- 1160.26.0350 Boehringer Ingelheim Investigational Site
-
Greensboro, North Carolina, Estados Unidos
- 1160.26.0322 Boehringer Ingelheim Investigational Site
-
High Point, North Carolina, Estados Unidos
- 1160.26.0173 Boehringer Ingelheim Investigational Site
-
Lexington, North Carolina, Estados Unidos
- 1160.26.0108 Boehringer Ingelheim Investigational Site
-
Pinehurst, North Carolina, Estados Unidos
- 1160.26.0006 Boehringer Ingelheim Investigational Site
-
Statesville, North Carolina, Estados Unidos
- 1160.26.0002 Boehringer Ingelheim Investigational Site
-
Statesville, North Carolina, Estados Unidos
- 1160.26.0069 Boehringer Ingelheim Investigational Site
-
Wilmington, North Carolina, Estados Unidos
- 1160.26.0372 Boehringer Ingelheim Investigational Site
-
Winston-Salem, North Carolina, Estados Unidos
- 1160.26.0094 Boehringer Ingelheim Investigational Site
-
Winston-Salem, North Carolina, Estados Unidos
- 1160.26.0425 Boehringer Ingelheim Investigational Site
-
-
North Dakota
-
Grand Forks, North Dakota, Estados Unidos
- 1160.26.0102 Boehringer Ingelheim Investigational Site
-
Jamestown, North Dakota, Estados Unidos
- 1160.26.0222 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Akron, Ohio, Estados Unidos
- 1160.26.0203 Boehringer Ingelheim Investigational Site
-
Canal Fulton, Ohio, Estados Unidos
- 1160.26.0434 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Estados Unidos
- 1160.26.0083 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Estados Unidos
- 1160.26.0402 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Estados Unidos
- 1160.26.0426 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Estados Unidos
- 1160.26.0479 Boehringer Ingelheim Investigational Site
-
Cleveland, Ohio, Estados Unidos
- 1160.26.0263 Boehringer Ingelheim Investigational Site
-
Cleveland, Ohio, Estados Unidos
- 1160.26.0480 Boehringer Ingelheim Investigational Site
-
Columbus, Ohio, Estados Unidos
- 1160.26.0267 Boehringer Ingelheim Investigational Site
-
Dayton, Ohio, Estados Unidos
- 1160.26.0035 Boehringer Ingelheim Investigational Site
-
Fairview Park, Ohio, Estados Unidos
- 1160.26.0150 Boehringer Ingelheim Investigational Site
-
Kettering, Ohio, Estados Unidos
- 1160.26.0201 Boehringer Ingelheim Investigational Site
-
Lorain, Ohio, Estados Unidos
- 1160.26.0223 Boehringer Ingelheim Investigational Site
-
Lyndhurst, Ohio, Estados Unidos
- 1160.26.0214 Boehringer Ingelheim Investigational Site
-
Sandusky, Ohio, Estados Unidos
- 1160.26.0275 Boehringer Ingelheim Investigational Site
-
Westlake, Ohio, Estados Unidos
- 1160.26.0103 Boehringer Ingelheim Investigational Site
-
-
Oklahoma
-
Bartlesville, Oklahoma, Estados Unidos
- 1160.26.0155 Boehringer Ingelheim Investigational Site
-
Tulsa, Oklahoma, Estados Unidos
- 1160.26.0435 Boehringer Ingelheim Investigational Site
-
-
Oregon
-
Corvallis, Oregon, Estados Unidos
- 1160.26.0139 Boehringer Ingelheim Investigational Site
-
Eugene, Oregon, Estados Unidos
- 1160.26.0325 Boehringer Ingelheim Investigational Site
-
Hillsboro, Oregon, Estados Unidos
- 1160.26.0078 Boehringer Ingelheim Investigational Site
-
Portland, Oregon, Estados Unidos
- 1160.26.0245 Boehringer Ingelheim Investigational Site
-
Springfield, Oregon, Estados Unidos
- 1160.26.0133 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos
- 1160.26.0301 Boehringer Ingelheim Investigational Site
-
Altoona, Pennsylvania, Estados Unidos
- 1160.26.0454 Boehringer Ingelheim Investigational Site
-
Camp Hill, Pennsylvania, Estados Unidos
- 1160.26.0295 Boehringer Ingelheim Investigational Site
-
Hershey, Pennsylvania, Estados Unidos
- 1160.26.0294 Boehringer Ingelheim Investigational Site
-
Jenkintown, Pennsylvania, Estados Unidos
- 1160.26.0369 Boehringer Ingelheim Investigational Site
-
Jersey Shore, Pennsylvania, Estados Unidos
- 1160.26.0303 Boehringer Ingelheim Investigational Site
-
Lancaster, Pennsylvania, Estados Unidos
- 1160.26.0431 Boehringer Ingelheim Investigational Site
-
Langhorne, Pennsylvania, Estados Unidos
- 1160.26.0168 Boehringer Ingelheim Investigational Site
-
Meadowbrook, Pennsylvania, Estados Unidos
- 1160.26.0293 Boehringer Ingelheim Investigational Site
-
Newton, Pennsylvania, Estados Unidos
- 1160.26.0025 Boehringer Ingelheim Investigational Site
-
Norristown, Pennsylvania, Estados Unidos
- 1160.26.0394 Boehringer Ingelheim Investigational Site
-
Philadelphia, Pennsylvania, Estados Unidos
- 1160.26.0158 Boehringer Ingelheim Investigational Site
-
Philadelphia, Pennsylvania, Estados Unidos
- 1160.26.0181 Boehringer Ingelheim Investigational Site
-
Philadelphia, Pennsylvania, Estados Unidos
- 1160.26.0416 Boehringer Ingelheim Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos
- 1160.26.0344 Boehringer Ingelheim Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos
- 1160.26.0466 Boehringer Ingelheim Investigational Site
-
Sellersville, Pennsylvania, Estados Unidos
- 1160.26.0208 Boehringer Ingelheim Investigational Site
-
Uniontown, Pennsylvania, Estados Unidos
- 1160.26.0465 Boehringer Ingelheim Investigational Site
-
Upland, Pennsylvania, Estados Unidos
- 1160.26.0400 Boehringer Ingelheim Investigational Site
-
Wynnewood, Pennsylvania, Estados Unidos
- 1160.26.0032 Boehringer Ingelheim Investigational Site
-
Wyomissing, Pennsylvania, Estados Unidos
- 1160.26.0067 Boehringer Ingelheim Investigational Site
-
-
Rhode Island
-
Pawtucket, Rhode Island, Estados Unidos
- 1160.26.0212 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Beaufort, South Carolina, Estados Unidos
- 1160.26.0007 Boehringer Ingelheim Investigational Site
-
Charleston, South Carolina, Estados Unidos
- 1160.26.0383 Boehringer Ingelheim Investigational Site
-
Greenville, South Carolina, Estados Unidos
- 1160.26.0313 Boehringer Ingelheim Investigational Site
-
Mount Pleasant, South Carolina, Estados Unidos
- 1160.26.0450 Boehringer Ingelheim Investigational Site
-
Spartanburg, South Carolina, Estados Unidos
- 1160.26.0166 Boehringer Ingelheim Investigational Site
-
Summerville, South Carolina, Estados Unidos
- 1160.26.0008 Boehringer Ingelheim Investigational Site
-
West Columbia, South Carolina, Estados Unidos
- 1160.26.0468 Boehringer Ingelheim Investigational Site
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos
- 1160.26.0348 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos
- 1160.26.0084 Boehringer Ingelheim Investigational Site
-
Germantown, Tennessee, Estados Unidos
- 1160.26.0062 Boehringer Ingelheim Investigational Site
-
Johnson City, Tennessee, Estados Unidos
- 1160.26.0370 Boehringer Ingelheim Investigational Site
-
Nashville, Tennessee, Estados Unidos
- 1160.26.0323 Boehringer Ingelheim Investigational Site
-
Nashville, Tennessee, Estados Unidos
- 1160.26.0395 Boehringer Ingelheim Investigational Site
-
Oak Ridge, Tennessee, Estados Unidos
- 1160.26.0474 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Austin, Texas, Estados Unidos
- 1160.26.0129 Boehringer Ingelheim Investigational Site
-
Austin, Texas, Estados Unidos
- 1160.26.0410 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Estados Unidos
- 1160.26.0156 Boehringer Ingelheim Investigational Site
-
Fort Worth, Texas, Estados Unidos
- 1160.26.0315 Boehringer Ingelheim Investigational Site
-
Fort Worth, Texas, Estados Unidos
- 1160.26.0444 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Estados Unidos
- 1160.26.0447 Boehringer Ingelheim Investigational Site
-
Killeen, Texas, Estados Unidos
- 1160.26.0483 Boehringer Ingelheim Investigational Site
-
Lubbock, Texas, Estados Unidos
- 1160.26.0335 Boehringer Ingelheim Investigational Site
-
McKinney, Texas, Estados Unidos
- 1160.26.0230 Boehringer Ingelheim Investigational Site
-
Plano, Texas, Estados Unidos
- 1160.26.0467 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Estados Unidos
- 1160.26.0013 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Estados Unidos
- 1160.26.0269 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Estados Unidos
- 1160.26.0307 Boehringer Ingelheim Investigational Site
-
San Marcos, Texas, Estados Unidos
- 1160.26.0285 Boehringer Ingelheim Investigational Site
-
Tyler, Texas, Estados Unidos
- 1160.26.0215 Boehringer Ingelheim Investigational Site
-
Tyler, Texas, Estados Unidos
- 1160.26.0367 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Arlington, Virginia, Estados Unidos
- 1160.26.0195 Boehringer Ingelheim Investigational Site
-
Charlottesville, Virginia, Estados Unidos
- 1160.26.0453 Boehringer Ingelheim Investigational Site
-
Chesapeake, Virginia, Estados Unidos
- 1160.26.0053 Boehringer Ingelheim Investigational Site
-
Danville, Virginia, Estados Unidos
- 1160.26.0098 Boehringer Ingelheim Investigational Site
-
Falls Church, Virginia, Estados Unidos
- 1160.26.0386 Boehringer Ingelheim Investigational Site
-
Fredericksburg, Virginia, Estados Unidos
- 1160.26.0428 Boehringer Ingelheim Investigational Site
-
Harrisonburg, Virginia, Estados Unidos
- 1160.26.0311 Boehringer Ingelheim Investigational Site
-
Newport News, Virginia, Estados Unidos
- 1160.26.0292 Boehringer Ingelheim Investigational Site
-
Norfolk, Virginia, Estados Unidos
- 1160.26.0224 Boehringer Ingelheim Investigational Site
-
Salem, Virginia, Estados Unidos
- 1160.26.0220 Boehringer Ingelheim Investigational Site
-
Winchester, Virginia, Estados Unidos
- 1160.26.0317 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Bellevue, Washington, Estados Unidos
- 1160.26.0287 Boehringer Ingelheim Investigational Site
-
Bellingham, Washington, Estados Unidos
- 1160.26.0050 Boehringer Ingelheim Investigational Site
-
Burien, Washington, Estados Unidos
- 1160.26.0040 Boehringer Ingelheim Investigational Site
-
Olympia, Washington, Estados Unidos
- 1160.26.0298 Boehringer Ingelheim Investigational Site
-
Spokane, Washington, Estados Unidos
- 1160.26.0250 Boehringer Ingelheim Investigational Site
-
Tacoma, Washington, Estados Unidos
- 1160.26.0256 Boehringer Ingelheim Investigational Site
-
Wenatchee, Washington, Estados Unidos
- 1160.26.0024 Boehringer Ingelheim Investigational Site
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos
- 1160.26.0193 Boehringer Ingelheim Investigational Site
-
Clarksburg, West Virginia, Estados Unidos
- 1160.26.0169 Boehringer Ingelheim Investigational Site
-
Huntington, West Virginia, Estados Unidos
- 1160.26.0365 Boehringer Ingelheim Investigational Site
-
-
Wisconsin
-
Elkhorn, Wisconsin, Estados Unidos
- 1160.26.0072 Boehringer Ingelheim Investigational Site
-
Green Bay, Wisconsin, Estados Unidos
- 1160.26.0234 Boehringer Ingelheim Investigational Site
-
Madison, Wisconsin, Estados Unidos
- 1160.26.0099 Boehringer Ingelheim Investigational Site
-
Madison, Wisconsin, Estados Unidos
- 1160.26.0242 Boehringer Ingelheim Investigational Site
-
Marshfield, Wisconsin, Estados Unidos
- 1160.26.0359 Boehringer Ingelheim Investigational Site
-
Milwaukee, Wisconsin, Estados Unidos
- 1160.26.0461 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Moscow, Federación Rusa
- 1160.26.1501 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1502 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1503 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1504 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1505 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1506 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1507 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1508 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1509 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1510 Boehringer Ingelheim Investigational Site
-
Moscow, Federación Rusa
- 1160.26.1511 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Federación Rusa
- 1160.26.1512 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Federación Rusa
- 1160.26.1513 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Federación Rusa
- 1160.26.1514 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Federación Rusa
- 1160.26.1515 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Manila, Filipinas
- 1160.26.1421 Philippine General Hospital
-
Manila, Filipinas
- 1160.26.1422 Manila Doctors Hospital
-
Pasig City, Filipinas
- 1160.26.1424 The Medical City
-
Quezon City, Filipinas
- 1160.26.1423 Philippine Heart Center
-
Quezon City, Filipinas
- 1160.26.1425 St Lukes Medical Center
-
-
-
-
-
Espoo, Finlandia
- 1160.26.0856 Boehringer Ingelheim Investigational Site
-
HUS, Finlandia
- 1160.26.0851 Boehringer Ingelheim Investigational Site
-
Jyväskylä, Finlandia
- 1160.26.0859 Boehringer Ingelheim Investigational Site
-
Kuopio, Finlandia
- 1160.26.0855 Boehringer Ingelheim Investigational Site
-
Lappeenranta, Finlandia
- 1160.26.0857 Boehringer Ingelheim Investigational Site
-
OYS, Finlandia
- 1160.26.0854 Boehringer Ingelheim Investigational Site
-
Pori, Finlandia
- 1160.26.0858 Boehringer Ingelheim Investigational Site
-
Tampere, Finlandia
- 1160.26.0852 Boehringer Ingelheim Investigational Site
-
Turku, Finlandia
- 1160.26.0853 Boehringer Ingelheim Investigational Site
-
-
-
-
-
ABBEVILLE cedex, Francia
- 1160.26.0875A Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882A Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882B Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882C Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882D Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882E Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882G Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882H Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882I Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882K Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0882L Boehringer Ingelheim Investigational Site
-
Angers, Francia
- 1160.26.0884A Boehringer Ingelheim Investigational Site
-
Cholet, Francia
- 1160.26.0887A Boehringer Ingelheim Investigational Site
-
Gap, Francia
- 1160.26.0889A Boehringer Ingelheim Investigational Site
-
Grenoble, Francia
- 1160.26.0888A Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879A Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879B Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879C Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879E Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879F Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879G Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879H Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0879S Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0880A Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0880F Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0880G Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0880J Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0881A Boehringer Ingelheim Investigational Site
-
Joue les Tours, Francia
- 1160.26.0881D Boehringer Ingelheim Investigational Site
-
Joué les Tours, Francia
- 1160.26.0880B Boehringer Ingelheim Investigational Site
-
Joué les Tours, Francia
- 1160.26.0880C Boehringer Ingelheim Investigational Site
-
Joué les Tours, Francia
- 1160.26.0880D Boehringer Ingelheim Investigational Site
-
Joué les Tours, Francia
- 1160.26.0880E Boehringer Ingelheim Investigational Site
-
Langres, Francia
- 1160.26.0874A Boehringer Ingelheim Investigational Site
-
Langres, Francia
- 1160.26.0874B Boehringer Ingelheim Investigational Site
-
Paris, Francia
- 1160.26.0871A Boehringer Ingelheim Investigational Site
-
TOULOUSE cedex, Francia
- 1160.26.0873A Boehringer Ingelheim Investigational Site
-
Tourcoing, Francia
- 1160.26.0886A Boehringer Ingelheim Investigational Site
-
VALENCIENNES cedex, Francia
- 1160.26.0872A Boehringer Ingelheim Investigational Site
-
Valenciennes, Francia
- 1160.26.0872B Boehringer Ingelheim Investigational Site
-
Valenciennes cedex, Francia
- 1160.26.0872C Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alexandroupolis, Grecia
- 1160.26.0908 University Hospital of Alexandroupolis
-
Athens, Grecia
- 1160.26.0901 General Hospital "Alexandra", Therapeutic Clinic UOA
-
Athens, Grecia
- 1160.26.0906 General Hospital ";Evangelismos"
-
Athens, Grecia
- 1160.26.0907 "Pammakaristos" Hospital of Athens
-
Athens, Grecia
- 1160.26.0915 "Hippokratio" Hospital of Athens
-
Kalamaria-Thessaloniki, Grecia
- 1160.26.0914 2nd IKA Hospital, Thessaloniki
-
Larissa, Grecia
- 1160.26.0904 General Hospital of Larissa
-
Larissa, Grecia
- 1160.26.0913 University Hospital of Larissa
-
Leivadia, Grecia
- 1160.26.0912 General Hospital of Leivadia
-
Thessaloniki, Grecia
- 1160.26.0902 General Hospital " Papageorgiou"
-
Thiva, Grecia
- 1160.26.0910 General Hospital of Thiva
-
Trikala, Grecia
- 1160.26.0903 General Hospital of Trikala
-
Voula - Athens, Grecia
- 1160.26.0905 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- 1160.26.1001 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 1160.26.1002 Boehringer Ingelheim Investigational Site
-
Kowloon, Hong Kong
- 1160.26.1003 Boehringer Ingelheim Investigational Site
-
Kowloon, Hong Kong
- 1160.26.1004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Budapest, Hungría
- 1160.26.1011 Boehringer Ingelheim Investigational Site
-
Budapest, Hungría
- 1160.26.1012 Boehringer Ingelheim Investigational Site
-
Budapest, Hungría
- 1160.26.1013 Boehringer Ingelheim Investigational Site
-
Budapest, Hungría
- 1160.26.1014 Boehringer Ingelheim Investigational Site
-
Budapest, Hungría
- 1160.26.1015 Boehringer Ingelheim Investigational Site
-
Budapest, Hungría
- 1160.26.1016 Boehringer Ingelheim Investigational Site
-
Gyongyos, Hungría
- 1160.26.1020 Boehringer Ingelheim Investigational Site
-
Komarom, Hungría
- 1160.26.1017 Boehringer Ingelheim Investigational Site
-
Pecs, Hungría
- 1160.26.1018 Boehringer Ingelheim Investigational Site
-
Veszprem, Hungría
- 1160.26.1019 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Ahmedabad, India
- 1160.26.1056 Boehringer Ingelheim Investigational Site
-
Ahmedabad, India
- 1160.26.1057 Boehringer Ingelheim Investigational Site
-
Bangalore, India
- 1160.26.1064 Boehringer Ingelheim Investigational Site
-
Bangalore, India
- 1160.26.1065 Boehringer Ingelheim Investigational Site
-
Bikaner, India
- 1160.26.1071 Boehringer Ingelheim Investigational Site
-
Chennai, India
- 1160.26.1066 Boehringer Ingelheim Investigational Site
-
Coimbatore, India
- 1160.26.1069 Boehringer Ingelheim Investigational Site
-
Hyderabad, India
- 1160.26.1062 Boehringer Ingelheim Investigational Site
-
Indore, India
- 1160.26.1058 Boehringer Ingelheim Investigational Site
-
Jaipur, India
- 1160.26.1053 Boehringer Ingelheim Investigational Site
-
Jaipur, India
- 1160.26.1073 Boehringer Ingelheim Investigational Site
-
Kerala, India
- 1160.26.1067 Boehringer Ingelheim Investigational Site
-
Kottayam, India
- 1160.26.1068 Boehringer Ingelheim Investigational Site
-
Lucknow, India
- 1160.26.1055 Boehringer Ingelheim Investigational Site
-
Ludhiana, India
- 1160.26.1051 Boehringer Ingelheim Investigational Site
-
Mumbai, India
- 1160.26.1060 Boehringer Ingelheim Investigational Site
-
Mysore, India
- 1160.26.1072 Boehringer Ingelheim Investigational Site
-
Nagpur, India
- 1160.26.1059 Boehringer Ingelheim Investigational Site
-
New Delhi, India
- 1160.26.1052 Boehringer Ingelheim Investigational Site
-
Pune, India
- 1160.26.1070 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Afula, Israel
- 1160.26.1110 Boehringer Ingelheim Investigational Site
-
Afula, Israel
- 1160.26.1121 Boehringer Ingelheim Investigational Site
-
Ashkelon, Israel
- 1160.26.1111 Boehringer Ingelheim Investigational Site
-
Be´er Scheva, Israel
- 1160.26.1102 Boehringer Ingelheim Investigational Site
-
Givatayim, Israel
- 1160.26.1117 Boehringer Ingelheim Investigational Site
-
Hadera, Israel
- 1160.26.1112 Boehringer Ingelheim Investigational Site
-
Haifa, Israel
- 1160.26.1091 Boehringer Ingelheim Investigational Site
-
Haifa, Israel
- 1160.26.1113 Boehringer Ingelheim Investigational Site
-
Haifa, Israel
- 1160.26.1114 Boehringer Ingelheim Investigational Site
-
Haifa, Israel
- 1160.26.1116 Boehringer Ingelheim Investigational Site
-
Haifa, Israel
- 1160.26.1118 Boehringer Ingelheim Investigational Site
-
Holon, Israel
- 1160.26.1105 Boehringer Ingelheim Investigational Site
-
Jerusalem, Israel
- 1160.26.1097 Boehringer Ingelheim Investigational Site
-
Jerusalem, Israel
- 1160.26.1101 Boehringer Ingelheim Investigational Site
-
Jerusalem, Israel
- 1160.26.1104 Boehringer Ingelheim Investigational Site
-
Jerusalem, Israel
- 1160.26.1106 Boehringer Ingelheim Investigational Site
-
Kfar Saba, Israel
- 1160.26.1119 Boehringer Ingelheim Investigational Site
-
Nazareth, Israel
- 1160.26.1115 Boehringer Ingelheim Investigational Site
-
Petah Tikva, Israel
- 1160.26.1096 Boehringer Ingelheim Investigational Site
-
Ramat Gan, Israel
- 1160.26.1093 Boehringer Ingelheim Investigational Site
-
Ramat Gan, Israel
- 1160.26.1094 Boehringer Ingelheim Investigational Site
-
Ramat Gan, Israel
- 1160.26.1095 Boehringer Ingelheim Investigational Site
-
Rehovot, Israel
- 1160.26.1100 Boehringer Ingelheim Investigational Site
-
Safed, Israel
- 1160.26.1103 Boehringer Ingelheim Investigational Site
-
Tel Hashomer, Israel
- 1160.26.1092 Boehringer Ingelheim Investigational Site
-
Tel Hashomer, Israel
- 1160.26.1098 Boehringer Ingelheim Investigational Site
-
Tel-Aviv, Israel
- 1160.26.1107 Boehringer Ingelheim Investigational Site
-
Tel-Aviv, Israel
- 1160.26.1108 Boehringer Ingelheim Investigational Site
-
Tel-Aviv, Israel
- 1160.26.1109 Boehringer Ingelheim Investigational Site
-
Tel-Aviv, Israel
- 1160.26.1120 Boehringer Ingelheim Investigational Site
-
Tel-Aviv, Israel
- 1160.26.1122 Boehringer Ingelheim Investigational Site
-
Zerifin, Israel
- 1160.26.1099 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Arezzo, Italia
- 1160.26.1169 Boehringer Ingelheim Investigational Site
-
Ascoli Piceno, Italia
- 1160.26.1172 Boehringer Ingelheim Investigational Site
-
Bentivoglio (BO), Italia
- 1160.26.1180 Boehringer Ingelheim Investigational Site
-
Bologna, Italia
- 1160.26.1161 Boehringer Ingelheim Investigational Site
-
Castelnuovo Garfagnana, Italia
- 1160.26.1163 Boehringer Ingelheim Investigational Site
-
Chieti, Italia
- 1160.26.1178 Boehringer Ingelheim Investigational Site
-
Colleferro, Italia
- 1160.26.1171 Boehringer Ingelheim Investigational Site
-
Cremona, Italia
- 1160.26.1174 Boehringer Ingelheim Investigational Site
-
Eboli, Italia
- 1160.26.1167 Boehringer Ingelheim Investigational Site
-
Isernia, Italia
- 1160.26.1168 Boehringer Ingelheim Investigational Site
-
Legnago, Italia
- 1160.26.1162 Boehringer Ingelheim Investigational Site
-
Mantova, Italia
- 1160.26.1177 Boehringer Ingelheim Investigational Site
-
Perugia SAN Sisto, Italia
- 1160.26.1165 Boehringer Ingelheim Investigational Site
-
Roma, Italia
- 1160.26.1175 Boehringer Ingelheim Investigational Site
-
San Bonifacio, Italia
- 1160.26.1181 Boehringer Ingelheim Investigational Site
-
San Daniele Del Friuli, Italia
- 1160.26.1173 Boehringer Ingelheim Investigational Site
-
Sassari, Italia
- 1160.26.1170 Boehringer Ingelheim Investigational Site
-
Sassari, Italia
- 1160.26.1176 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Abeno-ku, Osaka, Osaka, Japón
- 1160.26.1204 Boehringer Ingelheim Investigational Site
-
Aki-gun, Hiroshima, Japón
- 1160.26.1209 Boehringer Ingelheim Investigational Site
-
Aoba-ku, Sendai, Miyagi, Japón
- 1160.26.1193 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Fukuoka, Fukuoka, Japón
- 1160.26.1211 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Fukuoka, Fukuoka, Japón
- 1160.26.1225 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Kobe, Hyogo, Japón
- 1160.26.1221 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Osaka, Osaka, Japón
- 1160.26.1219 Boehringer Ingelheim Investigational Site
-
Fujioka-shi , Gunma-ken, Japón
- 1160.26.1229 Boehringer Ingelheim Investigational Site
-
Fukushima-shi,Fukushima-ken, Japón
- 1160.26.1232 Boehringer Ingelheim Investigational Site
-
Higashimatsushimashi, Miyagi-ken, Japón
- 1160.26.1228 Boehringer Ingelheim Investigational Site
-
Himeji, Hyogo, Japón
- 1160.26.1208 Boehringer Ingelheim Investigational Site
-
Iida, Nagano, Japón
- 1160.26.1214 Boehringer Ingelheim Investigational Site
-
Isesaki-shi,Gunma, Japón
- 1160.26.1240 Boehringer Ingelheim Investigational Site
-
Iwakuni, Yamaguchi, Japón
- 1160.26.1224 Boehringer Ingelheim Investigational Site
-
Izumi-ku, Sendai, Miyagi, Japón
- 1160.26.1194 Boehringer Ingelheim Investigational Site
-
Kamigyo-ku, Kyoto, Japón
- 1160.26.1241 Boehringer Ingelheim Investigational Site
-
Kawachinagano, Osaka, Japón
- 1160.26.1220 Boehringer Ingelheim Investigational Site
-
Kita-ku, Osaka, Osaka, Japón
- 1160.26.1203 Boehringer Ingelheim Investigational Site
-
Kita-ku, Sakai, Osaka, Japón
- 1160.26.1207 Boehringer Ingelheim Investigational Site
-
Komatsu-shi,Ishikawa -ken, Japón
- 1160.26.1231 Boehringer Ingelheim Investigational Site
-
Kyoto-shi,Kyoto, Japón
- 1160.26.1233 Boehringer Ingelheim Investigational Site
-
Matsumoto, Nagano, Japón
- 1160.26.1242 Boehringer Ingelheim Investigational Site
-
Minami-ku, Fukuoka, Fukuoka, Japón
- 1160.26.1210 Boehringer Ingelheim Investigational Site
-
Minato, Tokyo, Japón
- 1160.26.1218 Boehringer Ingelheim Investigational Site
-
Minato-ku, Nagoya, Aichi, Japón
- 1160.26.1200 Boehringer Ingelheim Investigational Site
-
Minato-ku, Nagoya, Aichi, Japón
- 1160.26.1201 Boehringer Ingelheim Investigational Site
-
Narashino, Chiba, Japón
- 1160.26.1216 Boehringer Ingelheim Investigational Site
-
Nishinomiya-shi,Hyogo, Japón
- 1160.26.1237 Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japón
- 1160.26.1223 Boehringer Ingelheim Investigational Site
-
Oota, Tokyo, Japón
- 1160.26.1197 Boehringer Ingelheim Investigational Site
-
Otaru, Hokkaido, Japón
- 1160.26.1212 Boehringer Ingelheim Investigational Site
-
Sagamihara, Kanagawa-ken, Japón
- 1160.26.1230 Boehringer Ingelheim Investigational Site
-
Sapporo-shi,Hokkai-do, Japón
- 1160.26.1238 Boehringer Ingelheim Investigational Site
-
Shibuya, Tokyo, Japón
- 1160.26.1217 Boehringer Ingelheim Investigational Site
-
Shinjuku, Tokyo, Japón
- 1160.26.1196 Boehringer Ingelheim Investigational Site
-
Shiroishi-ku, Sapporo, Hokkaido, Japón
- 1160.26.1191 Boehringer Ingelheim Investigational Site
-
Shiroishi-ku, Sapporo, Hokkaido, Japón
- 1160.26.1192 Boehringer Ingelheim Investigational Site
-
Suita, Osaka, Japón
- 1160.26.1206 Boehringer Ingelheim Investigational Site
-
Suita-shi, Osaka, Japón
- 1160.26.1235 Boehringer Ingelheim Investigational Site
-
Suita-shi, Osaka, Japón
- 1160.26.1236 Boehringer Ingelheim Investigational Site
-
Sumiyoshi-ku, Osaka, Osaka, Japón
- 1160.26.1205 Boehringer Ingelheim Investigational Site
-
Takatsuki-shi,Osaka, Japón
- 1160.26.1234 Boehringer Ingelheim Investigational Site
-
Tokorozawa, Saitama, Japón
- 1160.26.1215 Boehringer Ingelheim Investigational Site
-
Totsuka-ku, Yokohama, Kanagawa, Japón
- 1160.26.1198 Boehringer Ingelheim Investigational Site
-
Tsuchiura, Ibaragi, Japón
- 1160.26.1195 Boehringer Ingelheim Investigational Site
-
Ueda, Nagano, Japón
- 1160.26.1199 Boehringer Ingelheim Investigational Site
-
Wakayama, Wakayama, Japón
- 1160.26.1222 Boehringer Ingelheim Investigational Site
-
Yanagawa, Fukuoka, Japón
- 1160.26.1227 Boehringer Ingelheim Investigational Site
-
Yao, Osaka, Japón
- 1160.26.1243 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kajang,Selangor, Malasia
- 1160.26.1297 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malasia
- 1160.26.1291 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malasia
- 1160.26.1292 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malasia
- 1160.26.1294 Boehringer Ingelheim Investigational Site
-
Kuching, Malasia
- 1160.26.1293 Boehringer Ingelheim Investigational Site
-
Penang, Malasia
- 1160.26.1295 Boehringer Ingelheim Investigational Site
-
Penang, Malasia
- 1160.26.1296 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Durango, México
- 1160.26.1318 Hospital General "Dr. Santiago Ramón y Cajal
-
Guadalajara, México
- 1160.26.1311 Hospital Mexico-Americano
-
Guadalajara, México
- 1160.26.1317 hOSPITAL bERNARDETTE
-
Mexico, México
- 1160.26.1312 Hospital de Jesus
-
Mexico, México
- 1160.26.1319 Instituto Nacional de Cardiologia
-
México, México
- 1160.26.1314 Hospital 1o. de Octubre
-
San Luis Potosí, México
- 1160.26.1313 Hosp. Angeles Centro Medico del Potosi
-
San Luis Potosí, México
- 1160.26.1322 Hospital Central "Dr. Ignacio Morones Prieto"
-
-
-
-
-
Gjøvik, Noruega
- 1160.26.1396 Boehringer Ingelheim Investigational Site
-
Moss, Noruega
- 1160.26.1393 Boehringer Ingelheim Investigational Site
-
Nordbyhagen, Noruega
- 1160.26.1395 Boehringer Ingelheim Investigational Site
-
Oslo, Noruega
- 1160.26.1391 Boehringer Ingelheim Investigational Site
-
Oslo, Noruega
- 1160.26.1392 Boehringer Ingelheim Investigational Site
-
Oslo, Noruega
- 1160.26.1397 Boehringer Ingelheim Investigational Site
-
RUD, Noruega
- 1160.26.1394 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Adana, Pavo
- 1160.26.1715 Boehringer Ingelheim Investigational Site
-
Ankara, Pavo
- 1160.26.1711 Boehringer Ingelheim Investigational Site
-
Ankara, Pavo
- 1160.26.1713 Gazi Universitesi Tip Fakultesi Kardiyoloji Abd
-
Izmir, Pavo
- 1160.26.1714 Dokuz Eylul Universitesi Tip Fakultesi
-
-
-
-
-
Almelo, Países Bajos
- 1160.26.1344 Boehringer Ingelheim Investigational Site
-
Amsterdam, Países Bajos
- 1160.26.1331 Boehringer Ingelheim Investigational Site
-
Apeldoorn, Países Bajos
- 1160.26.1336 Boehringer Ingelheim Investigational Site
-
Breda, Países Bajos
- 1160.26.1332 Boehringer Ingelheim Investigational Site
-
Den Bosch, Países Bajos
- 1160.26.1337 Boehringer Ingelheim Investigational Site
-
Den Helder, Países Bajos
- 1160.26.1349 Boehringer Ingelheim Investigational Site
-
Deventer, Países Bajos
- 1160.26.1345 Boehringer Ingelheim Investigational Site
-
Dirksland, Países Bajos
- 1160.26.1360 Boehringer Ingelheim Investigational Site
-
Dordrecht, Países Bajos
- 1160.26.1348 Boehringer Ingelheim Investigational Site
-
Ede, Países Bajos
- 1160.26.1340 Boehringer Ingelheim Investigational Site
-
Eindhoven, Países Bajos
- 1160.26.1358 Boehringer Ingelheim Investigational Site
-
Enschede, Países Bajos
- 1160.26.1338 Boehringer Ingelheim Investigational Site
-
Goes, Países Bajos
- 1160.26.1343 Boehringer Ingelheim Investigational Site
-
Gorinchem, Países Bajos
- 1160.26.1347 Boehringer Ingelheim Investigational Site
-
Groningen, Países Bajos
- 1160.26.1333 Boehringer Ingelheim Investigational Site
-
Groningen, Países Bajos
- 1160.26.1355 Boehringer Ingelheim Investigational Site
-
Heerlen, Países Bajos
- 1160.26.1361 Boehringer Ingelheim Investigational Site
-
Hengelo, Países Bajos
- 1160.26.1339 Boehringer Ingelheim Investigational Site
-
Hilversum, Países Bajos
- 1160.26.1346 Boehringer Ingelheim Investigational Site
-
Hoorn, Países Bajos
- 1160.26.1356 Boehringer Ingelheim Investigational Site
-
Maastricht, Países Bajos
- 1160.26.1359 Boehringer Ingelheim Investigational Site
-
Meppel, Países Bajos
- 1160.26.1341 Boehringer Ingelheim Investigational Site
-
Rotterdam, Países Bajos
- 1160.26.1354 Boehringer Ingelheim Investigational Site
-
Sneek, Países Bajos
- 1160.26.1351 Boehringer Ingelheim Investigational Site
-
Spiijkenisse, Países Bajos
- 1160.26.1334 Boehringer Ingelheim Investigational Site
-
Terneuzen, Países Bajos
- 1160.26.1335 Boehringer Ingelheim Investigational Site
-
Tiel, Países Bajos
- 1160.26.1353 Boehringer Ingelheim Investigational Site
-
Tilburg, Países Bajos
- 1160.26.1352 Boehringer Ingelheim Investigational Site
-
Veldhoven, Países Bajos
- 1160.26.1350 Boehringer Ingelheim Investigational Site
-
Velp, Países Bajos
- 1160.26.1342 Boehringer Ingelheim Investigational Site
-
Venlo, Países Bajos
- 1160.26.1357 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bella Vista, Perú
- 1160.26.1415 Hospital Alberto Sabogal
-
Jesús María, Perú
- 1160.26.1411 Clinica San Felipe
-
San Isidro, Perú
- 1160.26.1412 Clínica Anglo Americana
-
San Martín de Porres, Perú
- 1160.26.1413 Hospital Cayetano Heredia
-
Urbanización Sto Tomas De San Borja, Perú
- 1160.26.1414 Clínica Vesalio
-
-
-
-
-
Gdynia, Polonia
- 1160.26.1436 Boehringer Ingelheim Investigational Site
-
Gdynia, Polonia
- 1160.26.1438 Boehringer Ingelheim Investigational Site
-
Gdynia Redlowo, Polonia
- 1160.26.1437 Boehringer Ingelheim Investigational Site
-
Katowice, Polonia
- 1160.26.1435 Boehringer Ingelheim Investigational Site
-
Krakow, Polonia
- 1160.26.1439 Boehringer Ingelheim Investigational Site
-
Krakow, Polonia
- 1160.26.1440 Boehringer Ingelheim Investigational Site
-
Pulawy, Polonia
- 1160.26.1433 Boehringer Ingelheim Investigational Site
-
Warsaw, Polonia
- 1160.26.1431 Boehringer Ingelheim Investigational Site
-
Warsaw, Polonia
- 1160.26.1432 Boehringer Ingelheim Investigational Site
-
Zabrze, Polonia
- 1160.26.1434 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Beijing, Porcelana
- 1160.26.0771 Boehringer Ingelheim Investigational Site
-
Beijing, Porcelana
- 1160.26.0772 Boehringer Ingelheim Investigational Site
-
Beijing, Porcelana
- 1160.26.0773 Boehringer Ingelheim Investigational Site
-
Beijing, Porcelana
- 1160.26.0774 Boehringer Ingelheim Investigational Site
-
Beijing, Porcelana
- 1160.26.0775 Boehringer Ingelheim Investigational Site
-
Beijing, Porcelana
- 1160.26.0783 Boehringer Ingelheim Investigational Site
-
Hangzhou, Porcelana
- 1160.26.0784 Boehringer Ingelheim Investigational Site
-
Harbin, Porcelana
- 1160.26.0776 Boehringer Ingelheim Investigational Site
-
QingDao, Porcelana
- 1160.26.0778 Boehringer Ingelheim Investigational Site
-
Shanghai, Porcelana
- 1160.26.0781 Boehringer Ingelheim Investigational Site
-
Shanghai, Porcelana
- 1160.26.0782 Boehringer Ingelheim Investigational Site
-
Shenyang, Porcelana
- 1160.26.0777 Boehringer Ingelheim Investigational Site
-
Shijiazhuang, Porcelana
- 1160.26.0780 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amadora, Portugal
- 1160.26.1456 Boehringer Ingelheim Investigational Site
-
Carnaxide, Portugal
- 1160.26.1451 Boehringer Ingelheim Investigational Site
-
Coimbra, Portugal
- 1160.26.1454 Boehringer Ingelheim Investigational Site
-
Coimbra, Portugal
- 1160.26.1459 Boehringer Ingelheim Investigational Site
-
Covilhã, Portugal
- 1160.26.1457 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1160.26.1453 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1160.26.1458 Boehringer Ingelheim Investigational Site
-
Porto, Portugal
- 1160.26.1455 Boehringer Ingelheim Investigational Site
-
Setúbal, Portugal
- 1160.26.1452 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Birmingham, Reino Unido
- 1160.26.1744 Boehringer Ingelheim Investigational Site
-
Chertsey, Reino Unido
- 1160.26.1746 Boehringer Ingelheim Investigational Site
-
Glasgow, Reino Unido
- 1160.26.1747 Boehringer Ingelheim Investigational Site
-
Harrow, Reino Unido
- 1160.26.1750 Boehringer Ingelheim Investigational Site
-
Hull, Reino Unido
- 1160.26.1753 Boehringer Ingelheim Investigational Site
-
Kirkcaldy, Fife, Reino Unido
- 1160.26.1755 Boehringer Ingelheim Investigational Site
-
London, Reino Unido
- 1160.26.1741 Boehringer Ingelheim Investigational Site
-
London, Reino Unido
- 1160.26.1756 Boehringer Ingelheim Investigational Site
-
Londonderry, Reino Unido
- 1160.26.1749 Boehringer Ingelheim Investigational Site
-
Newcastle upon Tyne, Reino Unido
- 1160.26.1742 Boehringer Ingelheim Investigational Site
-
Newport, Reino Unido
- 1160.26.1751 Boehringer Ingelheim Investigational Site
-
Northampton, Reino Unido
- 1160.26.1752 Boehringer Ingelheim Investigational Site
-
Portadown, County Atrim, Reino Unido
- 1160.26.1745 Boehringer Ingelheim Investigational Site
-
Romford, Essex, Reino Unido
- 1160.26.1743 Boehringer Ingelheim Investigational Site
-
Stoke-On-Trent, Reino Unido
- 1160.26.1754 Boehringer Ingelheim Investigational Site
-
York, Reino Unido
- 1160.26.1748 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bucharest, Rumania
- 1160.26.1471 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumania
- 1160.26.1472 Boehringer Ingelheim Investigational Site
-
Cluj Napoca, Rumania
- 1160.26.1478 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Singapore, Singapur
- 1160.26.1531 Boehringer Ingelheim Investigational Site
-
Singapore, Singapur
- 1160.26.1532 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bloemfontein, Sudáfrica
- 1160.26.1562 Boehringer Ingelheim Investigational Site
-
Boksburg, Sudáfrica
- 1160.26.1569 Boehringer Ingelheim Investigational Site
-
Cape Town, Sudáfrica
- 1160.26.1561 Boehringer Ingelheim Investigational Site
-
Johannesburg, Sudáfrica
- 1160.26.1564 Boehringer Ingelheim Investigational Site
-
Johannesburg, Sudáfrica
- 1160.26.1567 Boehringer Ingelheim Investigational Site
-
Johannesburg, Sudáfrica
- 1160.26.1568 Boehringer Ingelheim Investigational Site
-
Pretoria, Sudáfrica
- 1160.26.1566 Boehringer Ingelheim Investigational Site
-
Randburg, Sudáfrica
- 1160.26.1563 Boehringer Ingelheim Investigational Site
-
Somerset West, Sudáfrica
- 1160.26.1565 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Göteboerg, Suecia
- 1160.26.1633 Sahlgrenska Sjukhuset
-
Jönköping, Suecia
- 1160.26.1629 AVK-mott, Spec.M1, Länssjukhuset Ryhov
-
Linköping, Suecia
- 1160.26.1631 Universitetssjukhuset i Linköping
-
Malmö, Suecia
- 1160.26.1627 Hjärtmott. ING 35, Malmö Universitetssjukhus MAS
-
Norrköping, Suecia
- 1160.26.1625 Hjärtmott./Medicinkliniken, Vrinnevisjukhuset
-
Nässjö, Suecia
- 1160.26.1628 Rådhusg. 29, Lars Mörlids Läkarmottagning
-
Stockholm, Suecia
- 1160.26.1626 Hjärtkärllaboratoriet, Danderyds Sjukhus AB
-
Stockholm, Suecia
- 1160.26.1632 Capio S:t Görans Sjukhus
-
Stockholm, Suecia
- 1160.26.1634 Södersjukhuset
-
Umeå, Suecia
- 1160.26.1624 Klin. forskningscentrum, Norrlands Universitetssjukhus
-
Uppsala, Suecia
- 1160.26.1621 Kardiologiska kliniken, Akademiska Sjukhuset
-
Uppsala, Suecia
- 1160.26.1635 UCR/Uppsala
-
Västerås, Suecia
- 1160.26.1622 Hjärtmottagningen, Centrallasarettet
-
Örebro, Suecia
- 1160.26.1623 Kardiologiska kliniken, Universitetssjukhuset
-
-
-
-
-
Basel, Suiza
- 1160.26.1652 Boehringer Ingelheim Investigational Site
-
Bellinzona, Suiza
- 1160.26.1655 Boehringer Ingelheim Investigational Site
-
Bern, Suiza
- 1160.26.1651 Boehringer Ingelheim Investigational Site
-
Lugano, Suiza
- 1160.26.1654 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bangkok, Tailandia
- 1160.26.1701 Boehringer Ingelheim Investigational Site
-
Bangkok, Tailandia
- 1160.26.1702 Boehringer Ingelheim Investigational Site
-
Chiangmai, Tailandia
- 1160.26.1703 Boehringer Ingelheim Investigational Site
-
Khon Kaen, Tailandia
- 1160.26.1704 Boehringer Ingelheim Investigational Site
-
Muang Nakhonratchasima, Tailandia
- 1160.26.1705 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Changhua County, Taiwán
- 1160.26.1680 Boehringer Ingelheim Investigational Site
-
Hualien, Taiwán
- 1160.26.1683 Boehringer Ingelheim Investigational Site
-
Kaohsiung, Taiwán
- 1160.26.1682 Boehringer Ingelheim Investigational Site
-
Taichung, Taiwán
- 1160.26.1679 China Medical University Hospital
-
Tainan, Taiwán
- 1160.26.1681 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1671 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1672 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1673 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1674 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1675 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1676 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán
- 1160.26.1677 Boehringer Ingelheim Investigational Site
-
Taoyuan, Taiwán
- 1160.26.1678 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Dnyepropetrovsk, Ucrania
- 1160.26.1727 Boehringer Ingelheim Investigational Site
-
Kharkiv, Ucrania
- 1160.26.1726 Boehringer Ingelheim Investigational Site
-
Kharkov, Ucrania
- 1160.26.1724 Boehringer Ingelheim Investigational Site
-
Kharkov, Ucrania
- 1160.26.1725 Boehringer Ingelheim Investigational Site
-
Kiev, Ucrania
- 1160.26.1721 Boehringer Ingelheim Investigational Site
-
Kiev, Ucrania
- 1160.26.1722 Boehringer Ingelheim Investigational Site
-
Kiev, Ucrania
- 1160.26.1723 Boehringer Ingelheim Investigational Site
-
Kiev, Ucrania
- 1160.26.1728 Boehringer Ingelheim Investigational Site
-
Kiev, Ucrania
- 1160.26.1730 Boehringer Ingelheim Investigational Site
-
Kiev, Ucrania
- 1160.26.1731 Boehringer Ingelheim Investigational Site
-
Lvov, Ucrania
- 1160.26.1729 Boehringer Ingelheim Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Criterios de inclusión Pacientes con fibrilación auricular (FA) no valvular, con riesgo moderado a alto de accidente cerebrovascular o embolia sistémica con al menos un factor de riesgo adicional (es decir, ictus isquémico previo, AIT o embolia sistémica, disfunción ventricular izquierda, edad >=75 años, edad >=65 con diabetes mellitus, antecedentes de enfermedad arterial coronaria o hipertensión)
Criterio de exclusión
- Válvulas cardíacas protésicas que requieren anticoagulación per se, o enfermedad valvular hemodinámicamente relevante que se espera que requiera intervención quirúrgica durante el curso del estudio
- Accidente cerebrovascular grave e incapacitante en los 6 meses anteriores, o cualquier accidente cerebrovascular en los 14 días anteriores
- Condiciones asociadas con un mayor riesgo de sangrado
- Contraindicación para el tratamiento con warfarina
- Causas reversibles de fibrilación auricular (por ejemplo, cirugía cardíaca, embolia pulmonar, hipertiroidismo no tratado).
- Plan para realizar una ablación de venas pulmonares o cirugía para curar la FA
- Insuficiencia renal grave (aclaramiento de creatinina estimado <=30 ml/min)
- Endocarditis infecciosa activa
- Enfermedad hepática activa
- Mujeres embarazadas, lactantes o en edad fértil que se niegan a utilizar un método anticonceptivo médicamente aceptable durante todo el estudio
- Anemia (hemoglobina <100 g/L) o trombocitopenia (recuento de plaquetas <100 x 109/L)
- Pacientes que han desarrollado elevaciones de transaminasas tras la exposición a ximelagatrán
- Pacientes que hayan recibido un medicamento en investigación en los últimos 30 días o que estén participando en otro estudio de medicamentos
- Pacientes que el investigador no considere confiables en cuanto a los requisitos de seguimiento durante el estudio y/o el cumplimiento de la administración del fármaco del estudio, tengan una esperanza de vida menor que la duración esperada del ensayo debido a una enfermedad concomitante o padezcan alguna afección que, en opinión de del investigador, no permitiría una participación segura en el estudio (por ejemplo, adicción a las drogas, abuso de alcohol)
- Cualquier hipersensibilidad conocida a la galactosa si la warfarina utilizada contiene galactosa.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Dabigatrán dosis 2
dos veces al día
|
dos veces al día
|
Comparador activo: Warfarina
una vez al día
|
una vez al día
|
Comparador activo: Dabigatrán dosis 1
dos veces al día
|
dos veces al día
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Tasa de evento anual para el criterio de valoración compuesto de accidente cerebrovascular/SEE
Periodo de tiempo: 36 meses
|
Tiempo hasta la primera aparición de accidente cerebrovascular o evento embólico sistémico.
Tasa de evento anual (%) = número de sujetos con evento / sujeto-años * 100.
Años del sujeto = suma (fecha de finalización del estudio - fecha de aleatorización + 1) de todos los sujetos aleatorizados / 365,25
|
36 meses
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Tasa de evento anual para el criterio de valoración compuesto de accidente cerebrovascular/SEE/muerte por todas las causas
Periodo de tiempo: 36 meses
|
Tiempo hasta la primera aparición de accidente cerebrovascular, SEE o muerte por todas las causas.
Tasa de evento anual (%) = número de sujetos con evento / sujeto-años * 100.
Años del sujeto = suma (fecha de finalización del estudio - fecha de aleatorización + 1) de todos los sujetos aleatorizados / 365,25
|
36 meses
|
Tasa de evento anual: compuesto de accidente cerebrovascular/SEE/EP/IM/muerte vascular
Periodo de tiempo: 36 meses
|
Tiempo hasta la primera aparición de accidente cerebrovascular, evento embólico sistémico, embolia pulmonar, infarto de miocardio, incluido infarto de miocardio silencioso o muerte vascular.
Tasa de evento anual (%) = número de sujetos con evento / sujeto-años * 100.
Años del sujeto = suma (fecha de finalización del estudio - fecha de aleatorización + 1) de todos los sujetos aleatorizados / 365,25
|
36 meses
|
Eventos hemorrágicos (mayores y menores)
Periodo de tiempo: 36 meses
|
Tasa anual de eventos de hemorragias. Tasa de evento anual (%) = número de sujetos con evento / sujeto-años * 100. Años del sujeto = suma (fecha de finalización del estudio - fecha de aleatorización + 1) de todos los sujetos aleatorizados / 365,25 Las hemorragias mayores se adjudican, mientras que las hemorragias menores son informadas por el investigador. |
36 meses
|
Anomalías clínicamente relevantes para la hemorragia intracerebral y otras hemorragias intracraneales (ICH)
Periodo de tiempo: 36 meses
|
Pacientes con anomalías clínicas relevantes para hemorragia intracerebral, otra hemorragia intracraneal (HIC)
|
36 meses
|
Prueba de función hepática anormal
Periodo de tiempo: 36 meses
|
Número de sujetos con prueba de función hepática (LFT) anormal, es decir, ALT/AST>3xLSN y bilirrubina total>2xLSN
|
36 meses
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021.
- Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
- Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20.
- Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
- Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
- Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
- Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
- Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
- Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.
- Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.
- Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
- Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.
- Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015-1023. doi: 10.1136/heartjnl-2016-310358. Epub 2017 Feb 17.
- Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
- Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5.
- Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
- Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-07-0529. Epub 2016 Jan 28.
- Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015 Dec;170(6):1151-60. doi: 10.1016/j.ahj.2015.09.018. Epub 2015 Oct 3.
- Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.
- Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.
- Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014 Aug;100(15):1193-200. doi: 10.1136/heartjnl-2013-304872. Epub 2014 May 2.
- Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S, Pogue J, Wallentin L, Ezekowitz MD, Connolly SJ, Yusuf S; RE-LY Study Investigators. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-75. doi: 10.1016/j.amjcard.2013.10.045. Epub 2013 Nov 23.
- Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.
- Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.
- Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27.
- Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013 Nov 12;128(20):2192-201. doi: 10.1161/CIRCULATIONAHA.112.000491. Epub 2013 Sep 9.
- Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.
- Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6.
- Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6.
- Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.
- Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, Aisenberg J. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
- Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012 Nov 6;126(19):2309-16. doi: 10.1161/CIRCULATIONAHA.112.101808. Epub 2012 Oct 1.
- Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum In: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein].
- Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012 Apr 3;125(13):1605-16. doi: 10.1161/CIRCULATIONAHA.111.038729. Epub 2012 Feb 28.
- Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.
- Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.
- Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
- Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131-6. doi: 10.1161/CIRCULATIONAHA.110.977546. Epub 2011 Jan 3.
- Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735.
- Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6. Erratum In: Lancet Neurol. 2011 Jan;10(1):27.
- Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum In: N Engl J Med. 2010 Nov 4;363(19):1877.
- Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10, 810.e1-2. doi: 10.1016/j.ahj.2009.02.005.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1160.26
- 2005-003894-26 (Número EudraCT: EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Dabigatrán dosis 2
-
University of MinnesotaReclutamientoTrasplante de órganos sólidosEstados Unidos
-
University of South CarolinaMedical University of South Carolina; National Institute on Deafness and Other...Terminado
-
Dose Safety Inc.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Benaroya...SuspendidoGlucosa, sangre baja | Glucosa, sangre altaEstados Unidos
-
Memorial Sloan Kettering Cancer CenterActivo, no reclutandoTumores sólidos | Entrenamiento aeróbico preoperatorioEstados Unidos
-
Sanofi Pasteur, a Sanofi CompanyTerminado
-
Population Health Research InstituteHamilton Health Sciences CorporationTerminadoFibrilación auricular | Tromboembolismo venosoCanadá
-
Sanofi Pasteur, a Sanofi CompanyTerminado
-
University College, LondonMoorfields Eye Hospital NHS Foundation Trust; Targeted Genetics CorporationTerminadoDegeneración retinalReino Unido
-
Qilu Pharmaceutical Co., Ltd.Reclutamiento
-
University of PennsylvaniaNational Cancer Institute (NCI); PfizerTerminado